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Abstract 
Bacterial colonisation and biofilm formation onto total hip replacement femoral stems remain a 
serious complication detrimental to the success of total hip arthroplasty.  Current treatment 
procedures are accompanied by a heavy financial burden and morbidity for the patient while failing 
to guarantee a successful outcome with no reinfection.  In fact, infection rates after revision surgeries 
are typically higher than those for primary hip arthroplasties. 
This study investigates conceptual drug delivery channels to be incorporated within cementless 
femoral stems by applying additive manufacturing as enabler technology.  Drug delivery from these 
features is aimed at both prophylaxis and treatment of infection, with the latter emphasising the 
concept of creating a reinforceable antimicrobial depot inside the implant.  The novelty lies in 
facilitating the administration of multiple drug dosages from within the implant instead of the once-
off implant-based release strategies currently employed.   
Samples containing internal channels were designed based on analogies to drug delivery studies 
reporting on the commercial antibiotic loaded bone cement, Palacos R+G loaded with gentamicin. 
These samples were manufactured by LaserCUSING
®
 from Ti-6Al-4V ELI powder.  For 
prophylactic proof of concept, testing the channels were filled with Palacos R+G and challenged 
with two clinical isolates of Staphylococcus aureus in a bacterial growth inhibition study. 
Gentamicin-susceptible S.aureus Xen 36 was prevented from colonising for a minimum of 72 hours, 
whereas gentamicin resistant S.aureus Xen 31 reached the material within 24 h, signifying the 
importance of drug selection according to pathogen.  Hence, a solution of vancomycin in phosphate 
buffered saline pH 7.4 was used during in vitro reservoir release testing.  Three dosage injections 
were made into each of six samples during a cumulative incubation period of 100 h.  A 
biocompatible 5,000 Da molecular weight cut off polyethersulfone nanoporous membrane was 
employed as release rate-controlling device.  Released vancomycin was quantified with reversed 
phase high performance liquid chromatography.  The resulting release profile was characterised by 
means of the Korsmeyer-and-Peppas model for diffusion based drug delivery.  Constraint diffusion 
was identified as the mechanism controlling release, implying interplay between Fickian diffusion 
and polymer relaxation for effecting vancomycin release from within the reservoir. 
The concept created in this study provides a basis towards the development of full scale intelligent 
implants with multiple dose in situ drug delivery capabilities.  Implants incorporating this concept 
could aid in the perpetual struggle against infection by providing a new strategy for delivery of high 
level antibiotics directly to the site of infection. 
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Opsomming 
Kolonisering van bakterieë en die vorming van biofilms op totale heupvervanging femorale stamme 
bly ŉ ernstige komplikasie tot die sukses van ŉ totale heupvervanging.  Huidige 
behandelingsprosedures gaan gepaard met ŉ swaar finansiële las en infeksies vir die pasiënt sonder 
versekering van ŉ suksesvolle uitkoms.  Die voorkoms van infeksie is tipies hoër vir revisie 
prosedures as vir primêre heupvervangings. 
 
Hierdie studie ondersoek konseptuele dwelmvoorsieningskanale wat in sementvrye femorale stamme 
geïnkorporeer kan word deur middel van toevoegingsvervaardiging as bemagtigingstegnologie.  
Dwelmtoediening deur hierdie strukture is gemik op beide voorkoming en behandeling van infeksie 
met ŉ klem op die konsep van ŉ herlaaibare antimikrobiese depot in die implantaat.  Die nuwigheid 
lê in die fasilitasie van toediening van veelvuldige dwelm dosisse vanaf binne die implantaat in plaas 
van die huidige eenmalige implantaatgebaseerde toedieningstrategieë.  
 
Die ontwerp van monsters wat interne kanale bevat is baseer op vergelykings met literatuur op 
kommersiële beensement, Palacos R+G, wat met gentamisien belaai is.  Hierdie monsters is 
vervaardig met LaserCUSING
® 
van Ti-6Al-4V ELI poeier.  Kanale is gevul met Palacos R+G en 
uitgedaag met twee kliniese isolate van Staphylococcus aureus in ŉ bakteriële groei inhibisie studie.  
Gentamisien-sensitiewe S.aureus Xen 36 is verhoed tot kolonisasie vir ŉ minimum van 72 uur, 
terwyl gentamisien-weerstandige S.aureus Xen 31 die materiaal binne 24 uur bereik het.  Vervolgens 
was ‘n oplossing van vankomisien in fosfaatbuffer soutoplossing pH 7.4 gebruik tydens in vitro 
vrystellingstoetse.  Drie dosisse inspuitings is in elk van ses monsters oor ŉ inkubasietydperk van 
100 uur toegedien.  ŉ Biokompatibiele 5,000 Da molekulêre massa afsnypunt polietersulfoon 
nanoporeuse membraan is as vrystellingskoers regulerende apparaat gebruik.  Vrygestelde 
vankomisien is gekwantifiseer met omgekeerde fase hoë verrigting vloeistof-chromatografie.  Die 
vrystellingsprofiel is gekarakteriseer met die Korsmeyer-en-Peppas model vir diffusie gebaseerde 
dwelmtoediening.  Beperkte diffusie is geïdentifiseer as die meganisme wat vrystelling beheer.  Dit 
impliseer ŉ tussenspel in Fickiaanse diffusie en polimeer verslapping vir die tot stand bring van 
vankomisien vrystelling vanaf binne die reservoir. 
 
Hierdie konsep van die studie verskaf ŉ basis vir die ontwikkeling van volskaalse intelligente 
implantate met ŉ veelvuldige in situ dwelmtoedienings vermoë.  Implantate met hierdie konseptuele 
strukture kan steun gee aan die voortdurende stryd teen infeksie deur ŉ nuwe strategie daar te stel vir 
die toediening van hoë vlak antibiotika direk by die infeksie area. 
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Glossary 
Aseptic  The absence of infectious microorganisms  
Biocompatibility  Ability to not evoke an immune response when placed inside 
the human body  
Biofilm An extracellular matrix encapsulating bacterial communities  
Biomaterial  Material that does not evoke an immune response  
Chromophores Structures within a molecule which absorb light 
Chronic infection Long term persisting infection 
Colonisation  Bacterial adhesion in large numbers onto a surface   
Comorbidity Secondary diseases or disorders to a primary disease 
Culturing Process during which bacteria from an infectious wound is 
identified  
Cutaneous Pertaining to the skin 
Cytotoxicity Level of toxicity towards living cells 
Debridement Removal of all infected and dead tissue 
Drug-carrier Substance into which a drug is loaded for release 
Exogenous From outside of the body  
Extracellular matrix A protective structure consisting of biopolymers such as 
proteins, DNA, and polysaccharides   
Femoral stem The  part of a total hip replacement system that is implanted 
into the femur 
Glycosidic bond Bond between a carbohydrate and another group 
Gram-positive bacteria Bacteria that retains the crystal violet of a Gram-stain due to 
the presence of a thick multilayered peptidoglycan 
Gram-negative bacteria Bacteria that do not retain the Gram-stain due to the presence 
of an outer lipopolysaccharide membrane 
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Hematogenous Present in the bloodstream  
Hydrophilic Affinity for water 
Hydrophobic Aversion for water 
In situ In the actual place of origin 
In vitro Outside of a living organism 
In vivo Inside a living organism 
Intraosseous Inside the bone 
Isotopic cluster Cluster of similarly charged molecules on a mass spectrum 
consisting of different isotopic arrangements of its constituent 
elements 
Minimum inhibitory concentration Concentration of antimicrobial below which a bacterium can 
survive 
Mobile phase Transportation medium of samples in liquid chromatography 
Monoisotopic mass Mass of a molecule consisting only of its most abundant 
elemental isotopes 
Osseointegration Direct bond between the biomaterial surface and host bone  
Osteoarthritis Gradual degradation of the articular cartilage  
Osteoinductive  Enhancing the bone growth process   
Palacos R+G Commercial antibiotic loaded bone cement used in this project 
Pathogen  Disease causing microorganism 
Pathogenesis The mechanisms by which a disease develops  
Peptidoglycan A structural part of the bacterial cell wall 
Phenotype Specific characteristics of a microorganism due to the 
interaction of its genetic constitution with its surrounding 
environment  
Phosphate buffered saline A saline buffer often employed in microbiological research 
Planktonic Floating unattached in the blood or body fluid  
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Poly(methyl methacrylate) Polymer used as bone cement for cemented fixation of femoral 
stems 
Primary stability Stability of the femoral stem and the measure of micro-motions 
after implantation  
Prophylaxis Preventative measures against infection 
Quorum sensing Process that regulates gene expression and cell to cell 
communication amongst bacteria  
Resection Removal of bone, tissue or organs during surgery 
Retention To keep the implant in place during treatment  
Stationary phase Separation medium of compounds in liquid chromatography 
Virulence Measure of the ability to cause disease    
Zone of inhibition Area in a disc diffusion test in which all bacteria are killed  
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1.  Introduction 
1.1 Background 
The human hip, a synovial ball-and-socket joint, functions as the human body’s primary 
connection between the lower limbs and the trunk [1].  Consequently, the hip joint is constantly 
subjected to heavy loadings, supporting almost two thirds of the body weight during static 
conditions [2].  Furthermore, the hip joint is also responsible for facilitating everyday mobility 
such as walking, running and stair climbing, during which the hip has to sustain dynamic forces 
up to nearly five times that of the person’s body weight [2, 3].  A frequent ailment of the hip joint 
is the gradual degradation of the articular cartilage, which is symptomatic of osteoarthritis (OA) 
[2].  OA is the most frequent diagnosis for patients to undergo total hip replacement [4-7].  
Although different theories exist, the exact etiology of OA is still under dispute [2, 8].  
 
A reconstructive surgical procedure termed total hip arthroplasty (THA) or total hip replacement 
(THR) is typically performed to replace a problematic hip joint that does not respond to normal 
medical treatment, with a prosthetic substitute [9].  It is regarded as the most effective procedure 
for relieving the pain, disability and frustration attributed to OA [10].  Not only does this result in 
an enhanced quality of living for patients but can also reduce the psychological burden 
accompanying pain and disability.  Furthermore, the number of annual THA surgeries performed 
is on the increase [10-12].  With an average functional lifetime of 10 – 15 years for hip 
replacement implants, emphasis can be placed on the need for the enhancement on certain 
properties in order to increase implant longevity, especially in younger patients, and reduce the 
risk of implant failure [13]. 
 
The two most prevalent failure modes of hip replacement implants, not presented in any specific 
order, is the occurrence of aseptic loosening due to an increase in micromotions between the 
implant and bone interface in cementless fixation and the bone cement mantle and bone interface 
in cemented fixation [14]. It is argued that micromotions and consequently aseptic loosening, is 
attributed to an inadequate primary mechanical stability of the fit that the surgeon could achieve 
during surgery, and the stress shielding phenomenon at a later time after surgery [15-17].  
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A second, very serious obstacle, which is at the core of this study, is the prevalence of implant 
infection.  Implant infection currently poses one of the greatest challenges in orthopaedic surgery 
[18-20].  It occurs in both cementless (implant surface is in direct contact with bone), and 
cemented (implant is embedded in bone cement which forms a mantle between the implant and 
the bone) femoral stems [21, 22].  The infection rate for primary hip replacement surgeries is 
generally acctepted to be around 1% and infection rates for revision surgeries can be significantly 
higher [18, 19, 23].  This seemingly low percentage of primary THA infection is, however, 
significant because of the high (1,832,931 hip replacements in the Organisation for Ecomnomic 
Co-operation anf Development (OECD) countries alone for 2009) and increasing amount of THA 
procedures performed annually [10].  Furthermore, an increase in revision suregeries due to 
infection is also reported [12, 24]. 
 
Immediately following a THR surgery, a process dubbed “race to the surface” initiates, during 
which a race exist between tissue integration and the adhesion of bacterial cultures onto the 
implant to create a biofilm [25].  A biofilm is a specialized extracellular matrix which envelops 
the bacterial strain and is resistant to the human immune system as well as antibiotics [26-28].  
Thus, one of the most probable ways of currently removing a biofilm based infection is through 
surgical procedures and removal of the implant [29-32]. 
 
Even though various surgical interventions and protocols exist for the treatment of infected THR 
femoral stems, an optimal treatment strategy still remains an area of debate [33-35].  Giulieri et 
al. [36] proposed an algorithm as a guideline for deciding upon surgical and antibiotic procedures 
in the treatment of infected hip replacements.  The main surgical procedures for treatment of 
infection usually are either debridement with retention, one-stage or two-stage exchange 
arthroplasty [36]. The choice between which depends on factors such as the type of infection, 
time after surgery, damage to tissue and bone, condition of the implant, and miscellaneous factors 
which are situation specific [36].  Due to the nature of biofilm infection, whichever treatment 
procedure the surgeon in question chooses to follow cannot completely guarantee that there will 
be no re-infection [30, 35].  In some cases of serious and persistent deep infection, amputation 
might even be required to eradicate the infecting organism [37].  Even cases of mortality have 
been reported as a consequence of deep and chronic infection [38].  It is therefore argued that 
infection prevention is an extremely important strategy in ensuring implant success.    
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1.2 Problem Statement 
Amongst possible THR complications, prosthetic joint infection (PJI) is one of the most difficult 
and serious conditions to diagnose and manage [36, 39].  One strategy to prevent bacterial 
colonisation is the prophylactic utilisation of antibiotic-loaded bone cement (ALBC).  Drugs elute 
from the ALBC into the surrounding environment with the aim to kill surrounding pathogenic 
bacteria to prevent colonisation onto the biomaterial [40].  It is already a well-established and 
accepted practice in the case of cemented arthroplasties; however, it has been reported that 
typically less than 10% of the total loaded amount of antibiotic in the cement is effectively 
released during the first week [41].  Therefore debates exist about the dangers of this strategy to 
elute antibiotics at sub inhibitory concentrations that can cause bacteria to mutate and become 
resistant [40].  An appealing aspect of ALBC is that a range of clinically approved and 
commercially available products already exist. 
 
Recent research has shown the possibilities of customising cementless implant surfaces with 
alternative coatings containing nanotechnology [42].  The problem is however, that due to the 
limitations of the current manufacturing processes for cementless hip implants, the focus 
remained on coatings on the exterior of the implant.  This results in a once-off type of release 
without the possibility of administering more doses or drugs different from the ones originally 
used for surface coating.   
 
A type of hybrid femoral stem which ensures cementless fixation and is functionally customised 
for amtimicrobial elution from within the biomaterial in order to aid in the prevention of bacterial 
colonisation, could thus be useful in supporting the ongoing struggle against infection in the 
femoral canal.  Conventional manufacturing processes of hip replacement prostheses, however, 
do not allow for the intricate geometries and features that would accompany such customisation.  
In fact, THR femoral stems are largely manufactured from wrought material by subtractive 
processes. Custom designing and manufacturing for specific cases with short lead times is not yet 
readily applied in clinical practice [43].   
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A novel idea has been presented by Mueller et al. [44] to utilise additive manufacturing (AM) 
technologies in order to manufacture a femoral stem with internal channels, which can be used for 
a number of applications.  Figure 1.1 shows an adapted and recreated abstraction of the concept 
model manufactured at the Fraunhofer Institute for Machine Tools and Forming Technology 
(IWU) and is used here as an example to illustrate the concepts of Mueller et al. [44].  With the 
emergence of generative processes such as selective laser melting (SLM) and electron beam 
melting (EBM), complex geometries as presented in Figure 1.1 can be produced in THR femoral 
stems [44].  
 
 
 
Figure 1.1: Total hip replacement femoral stem with internal channels (adapted from [44])  
 
An important aspect to notice is that these developments are as of yet mostly conceptual and 
prototypes.  Although EBM acetabular cups have been granted regulatory clearance [45], heavy 
load bearing prostheses, for example, femoral hip stems, manufactured by AM technologies seem 
to lack evidence of being officially approved for clinical use through regulatory boards such as 
the United States Food and Drug Administration (FDA) [46].  Extensive testing and clinical trials 
are required in order to first prove the feasibility and the efficacy of these concepts [47, 48].  It is 
therefore necessary to investigate these aspects.   
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In this study, the validity of the concept of bacterial colonisation prevention by having an 
antimicrobial drug delivery substance embedded within the biomaterial is investigated.  Also 
investigated is the possibility of local drug delivery from within reservoir samples for multiple 
doses of an antibiotic typically used in the treatment of infection. 
 
The successful incorporation of such strategies in the future can potentially not only prove to have 
personal benefits for patients and medical staff, but also economical benefits for medical aid 
companies.  In the case of chronic infection, the complex two-stage procedure, which involves the 
interim implantation and removal of a temporary spacer, could possibly be substituted with a 
procedure in which an antimicrobial infiltrated, fully functional implant is inserted after 
debridement as a one-stage replacement.  Eventually, this could potentially reduce hospitalisation 
and operating theatre occupation time for many cases of chronic infection, leading to a reduction 
in cost for both the patient and medical aid companies. 
 
In summary, the problem statement is that bacterial colonisation onto the femoral stem and 
subsequent biofilm formation is a serious complication in orthopaedic surgery.  Strategies for 
cementless stems to deliver multiple doses of antibiotics for either prophylaxis or treatment 
locally to the site of infection do not yet exist.  Although concepts to address this situation by 
utilising AM for fabrication of internal channels from which antibiotics can be delivered have 
been presented, they still need to be evaluated with regard to the actual enabling of local drug 
delivery of antibiotics from within a femoral stem.   
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1.3 Research Question and Objectives 
The overall objective of this study is to contribute to the field of infection prevention and 
treatment strategies for cementless femoral stems.  This is to be achieved by investigating the 
prevention of bacterial colonisation onto and local drug release through AM titanium alloy 
samples containing conceptual drug delivery features that can be incorporated into cementless 
femoral stems.  Therefore, the research question is presented as: 
 
Can bacterial colonisation prevention onto, and controlled local drug release of multiple doses 
through Ti-6Al-4V ELI samples be achieved by embedding a drug delivery substance within 
samples containing conceptual drug delivery features manufactured by Selective Laser Melting? 
 
Subsequent issues to support the investigation of the main research question are summarised as 
follows: 
 
 What is the pathogenesis and mechanisms of chronic PJI? 
 What type of drugs and carriers are already clinically accepted and can be used to ensure 
clinical feasibility with regard to the antimicrobial products used?  
 What analogies can be made with drug elution studies to identify possible geometries for 
the features in which to embed the drug in order to effectively test the concept? 
 Can the concept of embedding antimicrobial drugs for the prevention of bacterial 
colonisation be expanded from prophylactic use to treatment of an already established 
infection?  
 Where does the strategy currently fit into the field of infection prevention and treatment?  
 
The following objectives have been identified and need to be achieved in order to answer the 
main research question: 
 
 Establishment of suitable conceptual drug delivery features based on literature 
 Additive manufacturing of samples with conceptual features for drug delivery on a 
suitable SLM machine 
 In vitro evaluation of prophylactic activity against susceptible S.aureus 
 In vitro evaluation of reinforcing reservoir controlled local drug delivery through passive 
diffusion across a commercial membrane. 
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1.4 Research Approach 
A comprehensive literature review will be performed to elucidate the relevant themes from 
different interacting scientific disciplines that combine to form the background for the 
experimental phase of the project.  The experimental phase is divided into three stages.  Stage 1 is 
the establishment of sample geometries followed by the utilisation of SLM for additive 
manufacturing of reservoir samples.  Stage 2 is the evaluation of the strategy towards prophylaxis 
and Stage 3 is the evaluation of reservoir drug release from within the samples for an antibiotic 
typically to be used in treatment of gram-positive bacterial infection scenarios. 
 
A computer aided design (CAD) concept model is to be developed in order to convey the 
message visually to any interested parties.  Since such implants do not yet exist, the concept will 
mainly focus on analogies to ALBC cement release studies in literature.   The zone of inhibition 
(ZOI) is the area in a two dimensional plane where no bacteria can survive due to the 
concentration of antimicrobial drug eluted from the drug carrier [49].  It is also important to note 
that the concept model will serve as a visual aid in conveying the ideas and the strategy of 
preventing colonisation from within the implant.  It is not claimed to be an optimised or 
commercially feasible design, but is meant to serve as a foundation for evaluating this novel drug 
delivery possibilities from within cementless hip stems, enabled by AM technologies.  However, 
once the concept is proven as an effective strategy, subsequent research projects can follow in 
order to optimise various aspects such as, but not limited to, design geometries, drug carrier and 
drug combination, as well as diagnostic procedures and process chain optimisation towards 
achieving a high value, quick to market transition to patient- or diagnose-specific THR femoral 
stems.  
 
Once a concept model with analogy to relevant literature has been developed, a sample of the 
feature can be isolated in order to test the concept.  These samples are then to be manufactured by 
SLM using default machine process parameters stored in the machine control software.  The build 
orientation of the part is also important, since the channels should be free of supports, placement 
should be at angles not exceeding the geometric process capabilities of the machine.   
 
Stage 2 will initiate with the identification and procurement of an appropriate drug-carrier 
combination to use in prophylactic testing.  To incorporate clinically relevant materials, an 
applicable commercially available ALBC is to be incorporated.  With collaboration from the 
Microbiology Department, the prophylactic efficacy is to be evaluated.  This will be done through 
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a modified Kirby-Bauer test procedure.  For this experiment, two clinical isolates of 
Staphylococcus aureus (S.aureus), one methicillin sensitive (Xen 36), and one methicillin 
resistant S.aureus (MRSA) (Xen 31), will be used.  It is expected to see very little activity against 
the resistant strain from the commercial ALBC bone cement.   
 
Stage 3 entails the evaluation of the application towards the local release of a reinforcement 
antibiotic, a vancomycin saline solution, from within the reservoirs inside the samples.  The 
means of release will be passive diffusion across a commercial nanoporous membrane with 
appropriate material and pore characteristics.  Samples will be filled with the vancomycin 
solution and placed within a phosphate buffered saline (PBS) buffer.  At specific time intervals 
aliquots will be taken and the concentration of vancomycin in the buffer quantified.   
 
The concentration of vancomycin will be quantified using reversed phase high performance liquid 
chromatography (RP-HPLC), a widely used separation technique for the analysis of a variety of 
solutions and mixtures, especially pharmaceuticals.  A release curve will then be constructed to 
describe the elution of the antibiotic from within the reservoir sample.  The efficacy of the 
antibiotic release depends on the ability of the mechanism to maintain concentrations of antibiotic 
released sufficiently above the minimum inhibitory concentrations (MICs) for pathogens the 
antibiotic is directed against. 
 
Together the three stages endeavour to evaluate a foundation for the release of drugs for infection 
prevention and treatment from within conceptual features aimed at cementless femoral hip stems 
enabled by AM technologies, SLM in particular.   
 
1.5 Limitations and Exclusions 
This study focuses on the femoral stem part of a complete THR system and excludes the 
acetabular cup, because emphasis is placed on infection which develops postoperatively in the 
femoral canal.  Another reason for the exclusion of the acetabular component is that the objective 
is to test whether a strategy of embedding or loading an antibiotic inside the stem can prevent 
bacterial colonisation on the implant surface. 
 
For manufacturing of the samples, SLM in the proprietary form of LaserCUSING
®
 by means of a 
M2 cusing system from Concept Laser will be utilised.  Other AM technologies such as EBM are 
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also recognised and reviewed in section 2.3.  LaserCUSING
®
, however, can produce parts with 
remarkable geometrical accuracy and enables the fabrication of a wide range of complex 
geometries with near full density.  Heart stents with strut dimensions as thin as 300 µm have 
previously been manufactured for demonstration purposes in house at the Rapid Product 
Development Laboratory (RPD), showcasing the capabilities of the machine. 
 
The material to use in the study is Ti-6Al-4V ELI (Grade 23) (medical grade) powder from 
Concept Laser.  Certain concerns about this alloy with regards to Aluminium attributing to 
diseases such as Alzheimer’s and cytotoxicity from possible excessive Vanadium-ion release has 
been raised in literature [50, 51].  There are however, diamond-like carbon (DLC) films that have 
been developed to prevent the release of ions from alloys used in biomedical applications [52].  
Thus, for the purpose of in vitro testing, the biomaterial Ti-6Al-4V ELI was deemed feasible. 
 
For purposes of proof of concept in vitro antimicrobial testing, it is important to utilise clinically 
approved products to reduce the amount of ambiguity with regard to clinical relevance.  
Therefore, a commercial PMMA ALBC, Palacos R+G (sponsored by Heraeus Medical), loaded 
with gentamicin, is to be used.  Similarly, an appropriate solution of the antibiotic vancomycin in, 
used in treating MRSA infections, in phosphate buffered saline (PBS) will be used for reservoir 
release testing.  The membrane to use for release testing were identified and procured through 
another in house study.  It is a 5000 Da molecular weight cut off (MWCO) non-biodegradable 
polyethersulfone (PES) ultrafiltration flat sheet membrane. 
 
The Bacterial strains for investigation were selected for both its clinical relevance and its ability 
to quickly colonise biomaterials to form biofilms [53, 54].  Although a variety of bacteria species 
can be found growing together in a biofilm, the use of two clinical isolate S.aureus strains will 
already reveal the efficacy of such colonisation prevention and future treatment strategies. 
 
The antimicrobial experiments will be performed under in vitro conditions at the Department of 
Microbiology at Stellenbosch University. 
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2. Integrated Approach to Total Hip Replacement, Infection 
Prevention and Additive Manufacturing – An Overview  
 
This chapter presents the literature reviewed in order to gain an understanding of the various 
disciplines which each form an integral part in the investigations of the study.  A holistic view of 
the issues surrounding the problem situation is sketched.  In order to achieve this, the sections 
have been arranged sequentially to incorporate and elaborate on the different significant processes 
that combine to each form part of the problem statement.  Figure 2.1 graphically presents the 
layout of the chapter.  According to the scope of the study, limits and exclusions with regard to 
the extent of the review are stated where necessary.   
     
 
Figure 2.1: Schematic representation of the structure and sequence (left to right) in which 
the literature review is presented 
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2.1 Total Hip Replacement 
In the 1994 National Institutes of Health Consensus Statement for Total Hip Replacement, the 
following excerpt can be found,  “Total hip replacement is an option for nearly all patients with 
diseases of the hip that cause chronic discomfort and significant functional impairment [55].”  
Thus, one would expect the amount THAs performed annually to be high, and it is indeed 
reflected as such in the OECD 2011 “Health at a Glance” publication [10]. 
 
Figure 2.2 shows the amount of THR surgeries performed per 100,000 inhabitants of OECD 
countries in 2009, or that of the closest year where data for 2009 was not readily available [10].  It 
is evident that the average amount of annual procedures for these selected countries is about 150 
per 100,000 inhabitants, which, when using the 2009 OECD population average of 1,221,954,000 
amounts to 1,832,931 THA surgeries performed in the OECD countries alone [56].  
 
 
Figure 2.2: Amount of Total Hip Replacement surgeries per 100 000 inhabitants of OECD 
countries in 2009 (or nearest year), [10] 
 
A high variability in the rate of THR occurrences exist between these countries.  Although 
specific explanations for this do not yet exist, Pabinger and Geissler [57] found significant 
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correlation between the number of THRs with economic indicators of health care expenditures- 
and gross domestic product per capita, which can account for some of the possible multitude of 
factors influencing this variability. 
 
The average estimated cost for hip replacements in 2007 is around 14,000 United States Dollars 
(USD) per procedure [10].  This means that, when applying the 2007 price, the annual monetary 
value of these procedures (1,832,931 multiplied by 14,000) is in the order of USD 256.6 billion.  
Furthermore, the already high occurrence of THA is on the increase [10].  Some of the suggested 
reasons for the increase in surgeries is the increase in life expectancy, yielding a greater number 
of people in the ageing population [58] as well as an increase in younger patients with developing 
hip problems [59].   
 
2.1.1 Femoral Stem Materials  
Femoral stems are manufactured from biomaterials.  Geetha et al. [60] defines a biomaterial to be 
either a natural or synthetic material, utilised in producing implants or any type of structure, that 
is utilised to treat or replace any damaged and diseased part of the body with the objective to 
restore  it to a functional state.  A very wide range of biomaterials therefore exists [61, 62].  For 
primary cementless femoral stems, however, metal alloys, and more specifically titanium alloys, 
can be regarded as the biomaterial of choice [60-62] (Table 2.2).  This is due to the excellent 
biocompatibility, corrosion resistance, high strength, ductility and fatigue behaviour of titanium 
alloys [60, 62, 63].  Furthermore, titanium alloys have a much lower elastic modulus than cobalt 
alloys or stainless steels, resulting in a reduction of stress shielding [64, 65].  Stress shielding is a 
phenomenon that occurs due to the mismatch between the elastic modulus of bone and implant 
material.  Most of the natural load is transferred by the stiffer implant and not anymore by the 
bone, which according to Wolff’s law causes the bone to remodel and resorb [17].  Figure 2.3 
displays the elastic modulus of a wide variety of titanium alloys in relation to that of human bone.  
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Figure 2.3: Different elastic moduli of various wrought implant alloy materials (adapted 
from [60]) 
 
Figure 2.3 encompass both so-called ‘first generation’ and ‘second generation’ biomaterials.  
They are distinguished by their crystal structure which can consist of α-phase (hexagonal close 
packed) and or ß-phase (body centred cubic) crystallographic configurations.  One of the 
advantages of these second generation alloys is their lower elastic modulus, which will also lead 
to a reduction in stress shielding.  Table 2.1, which is extracted and adapted from Geetha et al. 
[60] shows some of the mechanical properties of both first and second generation biomedical 
titanium alloys.   
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Table 2.1: Selected details regarding titanium biomedical alloys (adapted from [60]) 
Material Standard Elasticity Modulus 
[GPa] 
Alloy Type 
First generation (1950-1990)    
Commercially pure Ti (CpTi) ASTM 1341 100 α 
Ti-6Al-4V ELI (Grade 23) ASTM F136 110 α + ß 
Ti-6Al-4V (Grade 5) ASTM F1472 112 α + ß 
Ti-6Al-7Nb Wrought ASTM F1295 110 α + ß 
    
Second generation (1990-present)    
Ti-13Nb-13Zr Wrought ASTM F1713 79-84 Metastable ß 
Ti-12Mo-6Zr-2Fe ASTM F1813 74-85 ß 
Ti-35Nb-7Zr-5Ta  55 ß 
Ti-29Nb-13Ta-4.6Zr  65 ß 
Ti-15Mo-5Zr-3Al  82 ß 
 
 
Although ß-alloys with much lower stiffness are currently under development with great interest, 
the Ti-6Al-4V ELI (α + ß) remains one of the most utilised titanium alloys among commercially 
available cementless femoral stems [60, 66].  This is also evident from Table 2.2, which lists 
some of the more often reported on in literature, commercial primary cementless femoral stems, 
along with their constituent materials.   
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Table 2.2: Noteworthy primary cementless THR femoral stems 
Manufacturer Model Material(s) 
Biomet [67] Taperloc Ti-6Al-4V 
Zimmer [68] M/L Taper Ti-6Al-4V 
Zimmer [69] Fitmore Ti-6Al-4V 
Zimmer [70] Trabecular Metal Ti-6Al-4V/Ta-TM
a 
Zimmer [71] Alloclassic Zweymüller Ti-6Al-7Nb/Ti-6Al-4V 
Zimmer [72] VerSys Epoch CoCrMo/PEEK
b
/Ti-FM
c 
DePuy  [73] Summit Ti-alloy
d 
DePuy [74] S-ROM Ti-6Al-4V 
DePuy [75] TRI-LOCK Ti-alloy
d 
DePuy [76] Corail Ti-alloy
d 
Corin [77]   MetaFix Ti-6Al-4V 
Corin [78] TriFit TS Ti-alloy
e
/CpTi 
a ‘TM’ refers to the Zimmer proprietary name of Trabecular Metal 
b’PEEK’ refers to the polymer polyetheretherketone 
c ‘FM’ refers to Fiber Metal, indicating titanium in a very thin, fibrous physical state 
d 
Ti-alloy is the material referred to in the DePuy documents, however likely this is to be Ti-6Al-
4V, it cannot be assumed without proper confirmation, therefore the entry is kept similar to the 
original manufacturer’s documents. 
e 
The same as for (c), but since this is a different manufacturer, it has its own designation. 
 
 
From the materials specified in the manufacturer’s brochures (Table 2.2) it is evident that the Ti-
6Al-4V alloy is still predominantly used, despite concerns about the long term implications on 
Alzheimer’s disease from aluminium  and cytotoxicity of the vanadium alloying elements [50, 51, 
60].  Consequently, Ti-6Al-4V ELI (extra low interstitial) is deemed an appropriate material to 
utilise for AM of the samples with the M2 cusing system.   
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2.1.2 Cementless Fixation of Femoral Stems 
Cementless femoral stems are designed to establish a secure fixation via osseointegration and 
eventual bone ingrowth [21, 79].  It is important to distinguish between the terms 
osseointegration, bone ingrowth, and bone ongrowth.  Albrektsson et al. [21] and Brånemerk [80] 
have used the term osseointegration to describe the direct bond that is formed between the 
biomaterial surface and host bone.  The result of the bone remodelling process itself, by which 
new bone is formed to secure the implant in place is, depending on the surface morphology, 
referred to as either ongrowth or ingrowth [61, 81].  Therefore osseointegration can be regarded 
as the enabler, and its importance in achieving secure fixation underlined.  
 
The difference between bone ingrowth and ongrowth is depicted in Figure 2.4.  Ingrowth (left 
hand side schematic in Figure 2.4) describes the generation of new host bone and the growth of 
this bone into a porous layer on the biomaterial, securing the implant in place by means of 
physical integration [81].  Ongrowth (right hand side schematic in Figure 2.4) is also a means of 
implant fixation, but in this case, the surface of the biomaterial is roughened and without a porous 
layer with interstices into which host bone can grow [82].  Therefore, the host bone can only 
proliferate onto the roughened surface and is termed as such.  According to Black, ongrowth 
yields much less tensile support than ingrowth [61].  
 
 
Figure 2.4: Schematic representation of the difference between bone ingrowth (left) and 
bone ongrowth (right) 
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2.1.3 Fixation Failure Modes of Cementless Femoral Stems 
The loosening of cementless femoral stems is typically classified as either aseptic (in absence of 
any infectious pathogens) or septic (presence of infection) [83].  Aseptic loosening occurs 
typically due to mechanical phenomena.  It includes the prevalence of excessive micromotions (in 
excess of 150 µm) between the implant surface and bone interface as a result of an insufficient 
primary stability of the stem  and the stress shielding phenomenon during which bone remodels 
and resorbs due to a lack of load bearing stimulation [14-17].   
 
The emphasis in this study is, however, on reducing the risk of septic failure by addressing the 
issue of bacterial colonisation onto the biomaterial.  In Section 1.1 the process “race to the 
surface” was briefly mentioned, during which the biomaterial becomes conditioned with host 
proteins and a “race” initiates between osseointegration and the adhesion of bacteria [25]. If the 
implant surface is colonised by bacteria, they can enter biofilm mode of growth during which 
they encapsulate themselves in an extracellular matrix which is highly resistant to antibiotic 
penetration [26-28].  Therefore, extensive and expensive multiple stage surgical procedures 
during which the implant is removed and, after vigorous antibiotic regiments, a new one is 
eventually introduced  have become a clinical standard for attempting the eradication of an 
established prosthetic infection [20, 29-32].   
 
The negative influence of infection on prosthesis success and the patient’s quality of life, together 
with the expensive financial implications only emphasises the need for effective infection 
prevention and treatment strategies [18, 84]. 
 
2.2 Implant Infection after Total Hip Arthroplasty  
Infecrion can be described as an absence of a homeostatic balance between microorganisms and 
the tissue cells of the host [85].  Surgical intervention is required in order to attempt the 
eradication of an established infection, and despite best practices, some cases of serious and 
persistent infection can lead to implant removal, disfigurement, and even amputation or mortality 
[37, 38, 86, 87]. 
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Various attempts and advances have been made through history in the struggle against surgical 
wound infection.  In 1865 Sir Joseph Lister, a British surgeon, first introduced an antiseptic 
method for reducing wound infections [88].  Other major breakthroughs in reducing infections 
include the utilisation of rubber gloves in 1890 by W.S. Halsted and the introduction of a “Clean 
Air Operating Enlcosure” by Sir J. Charnley.  In 1964 Sir J. Charnley correlated the intensity of 
bacterial contamination in the operating theatre air with infections after surgery [89].  By filtering 
the air of the surgical theatre, he achieved a reduction in infection rate from 9.5% to 1.1%.  This 
was a major milestone for infection control in hip surgeries, and it revealed the importance of 
preventative aseptic conditions as to the earlier antiseptic paradigm [88].         
 
In this section, the mechanisms of infection after hip replacement surgery are briefly reviewed.  It 
is important to note that many themes with regard to the pathogenesis and persistence of 
infection, microbial behaviour and communication, are expert fields of science and research 
regarding the immense detail and complexity on cellular and gene expression level [90-92].  
Therefore, the review is presented at a level of detail as to keep relevance to the main theme of 
the current study.     
 
2.2.1 Overview of Infection  
The infection of a THR femoral stem can be classified into two main categories, depending on the 
duration after surgery before its onset.  They are termed exogenous and hematogenous 
respectively.  Pathogens responsible for exogenous infection would typically intrude the 
implantation site during surgery, or shortly after, while the surgical wound is still healing.  In 
hematogenous infections, the pathogen finds its way to the biomaterial by means of the host’s 
blood system.  There is no limit as to the time after surgery for the occurrence of hematogenous 
infection [93].   
 
Despite the time after surgery and the pathogen’s means of reaching the femoral stem, infection 
starts with the adherence of pathogens to the implanted biomaterial.  According to Darouiche [94] 
this process is dependent on the complex interaction between the femoral stem, the human host, 
and the pathogens.   
 
In order to further distinguish between the durations after surgery before manifestation of the 
infectious organism, exogenous infection can further be classified as ‘early’, occurring less than 
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two months after surgery, or ‘delayed’, occurring between three and twenty four months after 
surgery [11].  Pathogen sources include the operating theatre air, medical staff’s clothing, surgical 
tools, cutaneous bacteria, and bacteria already in the host [95].   
 
The wide variety of pathogenic sources is also reflected in the number of different infecting 
bacterial species that can be found in PJI sites, such as in the study of Berbari et al [96].  In their 
study, data about patients with THA and total knee arthroplasty (TKA) performed at the Mayo 
Clinic in Rochester, Minnesota, were obtained for the period of 1969 to 1991, during which 462 
cases of PJI have been identified in 460 patients.  A summary of the frequency of infecting 
organism from their study is presented in Table 2.3.  S.aureus was found to be one the main 
infecting species.  Similar findings with regard to staphylococcal species, and specifically 
S.aureus, as most frequent offending organisms have been published by both Pulido et al. [97] 
and Montanaro et al. [98].  It also reveals the high prevalence of S.aureus and the relevance of 
investigating antimicrobial efficacy against strains from this pathogen. 
              
Table 2.3:  Infecting organisms found in 462 prosthetic joint infections between 1969 and 
1991 after THA and TKA at the Mayo Clinic, Minnesota (adapted from [96]) 
Infecting Organism Number Percentage (%) 
S. aureus 101 22 
Polymicrobial etiology 88 19 
Coagulase-negative staphylococci (CNS) 86 19 
Negative culture 57 12 
Streptococci 42 9 
Gram-negative bacilli 38 8 
Anaerobes 29 6 
Other 21 5 
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2.2.2 Overview of Biofilm 
A biofilm is a collection of surface-adhering microorganisms, often from a variety of genera, 
embedded in an organic extracellular matrix, which is constituted from both the microorganisms’ 
secretions as well as compounds from the surrounding environment [29, 90].  The typical 
sequence of biofilm formation is presented in Figure 2.5.  The ability of bacteria growing in a 
biofilm to utilise these secretions, enable them to become resistant to various antibiotics and 
allows them to persist, leading to, amongst other, chronic prosthetic joint infections.  
Furthermore, the extracellular matrix also plays a pivotal role in establishing structural stability 
and a measure of protection for the bacteria growing as biofilm [28].  These types of infections 
can persist, showing very little response to host innate immune and inflammatory responses as 
well as antibiotic treatment [49]. 
 
 
Figure 2.5: A sequential representation of the biofilm formation process (adapted from [90]) 
 
The mechanism of biofilm formation is discussed with reference to Figure 2.5, which represents a 
schematic of the sequential steps during biofilm formation.  A biofilm typically begins with the 
reversible adhesion of a single species of planktonic bacteria onto the biomaterial surface via a 
variety of possible adhesive forces [29, 90, 93].  If the biomaterial is absent of protein 
conditioning, these bonds can typically include electrostatic processes, Van der Waals forces, 
hydrophobic processes, and hydrogen-bonds [26, 42].  In vivo, however, it becomes more 
complicated, since the biomaterial substrate is swiftly covered with proteic film, which then 
forms the new means of interaction with the bacteria [42].  
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It is important to note that the first stage of adhesion is reversible, and during this stage, bacteria 
are still susceptible to antibiotics.  The administering of prophylactic antibiotics strives to 
eliminate planktonic and reversibly attached bacteria, prohibiting them from reaching the state of 
irreversible adhesion.  If adhesion by a single species is successful, a rapid increase in the number 
of adhering bacteria follows.  This process is known as colonisation of the substratum.   
 
Once this has occurred, the bacteria can divide into daughter cells, which also bind to the surface.  
This results in a community of microcolonies, consisting of the original adhering bacteria as well 
as daughter cells from those that already began to multiply.  Amongst the adhering bacteria, a 
secretion of various polymers and acidic polysaccharides takes place.  The adhering bacteria, 
together with the produced extracellular compounds can then turn into a new substratum for other 
accreting bacteria species [90].  Typically, in vitro, the thickness of the biofilm grows to be 
around 50 µm, with the prevalence of vertical protrusions as the biofilm reach maturity [28].  A 
maximum resistance towards antibiotics appear in the mature stage of the biofilm.  The final stage 
is the dispersion stage, where certain areas of the biofilm becomes dissolved and some of the 
encased bacterial cells are set free to seed on other locations of the substratum and form new 
biofilms [90]. 
 
The mechanisms behind metabolic changes, mutation and communication amongst bacteria in 
biofilm mode of growth, are being studied continuously and are highly specialised fields 
respectively.  Therefore, only an overview of these concepts is presented in this document [28, 
93, 99, 100]. 
 
According to Francolini & Donelli [26], areas of importance with regards to the prevention and 
controlling of biofilms are, firstly, the need to inhibit any microbes from successfully colonising 
the material, the interference of cell-to-cell communications and the separation of an already 
established biofilm matrix, emphasising the need for the evaluation of effective colonisation 
preventing and drug delivery strategies [26]. 
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2.2.3 Treatment Procedures 
The goal of treatment for each case of an infectious hip replacement is the complete eradication 
of all present offending microorganisms and subsequent restoration of proper functionality to the 
implant [30].  These procedures include: 
 
 early debridement with retention  
 one-stage exchange  
 two-stage exchange,  
 permanent removal of the implant,  
 Girdlestone resection arthroplasty,  
 and chronic antibiotic suppression [11, 30, 101].   
 
The procedure of interest here is the two-stage exchange arthroplasty.  It has yielded some of the 
most satisfying results (>90% success rate in some cases [30, 102, 103]) and is typically the 
procedure regarded as the standard treatment for patients with developed abscesses and sinus 
tracts [11, 35, 103].  The first stage procedure involves the removal of the implant, a thorough 
debridement, followed by a minimum 4 week period of antibiotics during which patients have 
very little mobility and are also instructed to use non-weight bearing mobility methods [31, 33]. 
 
A temporary spacer, constituted from antibiotic loaded bone cement, is often implanted to help 
eradicate infection by eluting antibiotics locally at the site of infection and to allow a certain 
measure of mechanical support.  Only after antibiotic treatment and evidence of satisfying 
eradication of the infecting microorganisms, the second stage where a new functional implant is 
inserted can be performed [103].  This is where the interim period can be extended significantly, 
when screening of a joint aspirate turns out positive for cultures, the antibiotic treatment needs to 
be repeated before reimplantation of a functional prosthesis can occur [103].   
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2.2.4 Antimicrobial Drugs for Infection Prevention and Treatment  
An extensive range of antibiotics available to treat orthopaedic infections exist.  Zilberman and 
Elsner [85] summarised a collection of these antibiotics with regard to some of their respective 
properties.  Their full summary is presented in Appendix C.  When selecting an antimicrobial for 
prophylaxis, the antimicrobial should have a broad spectrum, whereas the antibiotic selection for 
treatment should be specific to the offending pathogen.  Gentamicin has been selected for 
prophylactic testing and vancomycin for sustained drug release from within the samples. 
 
2.2.4.1 Gentamicin  
Gentamicin is an aminoglycoside antibiotic which is derived from the fermentation of the 
bacterial species Micromonospora purpurea and Micromonospora echinospora [104].  It is a 
combination of three different main occurring chemical structures, gentamicins C1, C2, and C1a 
[105, 106].  Although more minor components have been discovered, these three are considered 
the main constituents of the gentamicin aminoglycoside.  It is recognised by the bonding of at 
least two amino monosaccharides via glycosidic bonds to a central structure which is termed an 
aminocylitol [106].  In the case of gentamicin, this aminocyclitol is 2-deoxystreptamine, to which 
amino saccharides, garosamine and purpurosamine, have each glycosidically bonded at carbon 
atoms 4 and 6 respectively [106, 107].  It is utilised inside ALBCs in the form of gentamicin 
sulfate, which has the physical appearance of a white to yellowish white powder [105]. 
 
Gentamicin exhibits various properties that make this a very suitable antibiotic for prophylactic 
administration, especially via addition to bone cement.  One such property is that it is relatively 
heat stable and therefore able to withstand the temperatures reached during polymerisation in 
PMMA bone cement.  Table 2.4, lists some of the notable physicochemical properties of the three 
major gentamicins that collectively exist as the gentamicin part of gentamicin sulfate [104, 105].  
The molecular weight in Table 2.4 is for each respective gentamicin only, and is exclusive of the 
molecular weight of sulphuric acid. 
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Table 2.4: Selected physicochemical properties of gentamicins [104, 105] 
Generic name Empirical 
Formula 
Molecular 
Weight [g/mol] 
Melting 
Point ºC 
Water 
Solubility 
pH (4% solution 
in water) 
Gentamicin C1 C21H43N5O7 477.6 218-237 50 mg/ml 3.5 - 5.5 
Gentamicin C2 C20H41N5O7 463.6 218-237 50 mg/ml 3.5 - 5.5 
Gentamicin C1a C19H41N5O7 449.5 218-237 50 mg/ml 3.5 - 5.5 
 
 
Gentamicin also exhibits a wide antibacterial spectrum.  It also acts synergistically against 
microbes along with a number of other antibiotics and is often used in bone cements as a 
combination with other antibiotics such as clindamycin or vancomycin [105, 108].  The 
antibacterial spectrum of gentamicin is listed in Table 2.5.   
 
Table 2.5: Antimicrobial spectrum of gentamicin [105] 
Gram-positive  Gram-negative Naturally Resistant 
S. aureus Pseudomonae anaerobes 
CNS Enterobacteriaceae streptococci 
Staphylococcus epidermidis  others 
 
 
Gentamicin exerts its bactericidal effect through the inhibition of prokaryotic protein synthesis by 
binding within the 30S subunit of the ribosome [106, 107].  It disrupts the translation process of 
the codons transcribed onto mRNA, the sequence of which was originally specified by the 
organism’s DNA for protein synthesis [105, 109].  Consequently, the polypeptide chain of the 
protein cannot be correctly synthesised and adequate protein synthesis does not occur.   
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2.2.4.2 Gentamicin Release from PMMA 
The process of antibiotic elution from the PMMA matrix has been extensively studied in the past 
four decades [110-112].  The release typically occurs in two definitive stages, an initial burst 
release of gentamicin into the surrounding fluid (typically within the first 24 hours [113]), 
followed by a steady sustained release which can last for an extensive period of time [110].  The 
exact mechanisms, however, by which antibiotics elute from PMMA bone cements currently still 
remains an area of debate and authors have expressed different opinions to the finer details of the 
process with regard to it being mainly a surface effect or a dissolution effect by which fluid 
slowly penetrates the PMMA matrix through imperfections such as cracks and pores [110].  Van 
de Belt et al. [41] have argued the release to be a combination of both, by which the initial burst 
release is mainly a surface dependent effect and the sustained release being a dissolution effect.  
This concept is illustrated in Figure 2.6.    
   
 
Figure 2.6: Schematic representation of different stages of antibiotic release from the 
PMMA matrix [41] 
 
A generic curve created from the results of various reports in literature representing the typical 
cumulative release behaviour of gentamicin over time is presented in Figure 2.7 [110, 114-116].  
In an ideal situation, the cumulative amount of drug release should reach a sufficiently high level 
in a short period of time and then either cease to elute or maintain effective concentrations, 
instead of continuing with a sustained slow and ineffective release [41].   
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Figure 2.7: Generic curve representing typical cumulative release of gentamicin from 
PMMA [110, 114-116] 
 
Various efforts to propose a mathematical model for describing the release of a drug randomly 
dispersed in a matrix have been reviewed by Lewis and Torrado et al. [113, 115].  Some of these 
models do not account for hydrophobicity of polymers such as PMMA and therefore cannot be 
assumed to be an accurate description of the real world process [113].  Modifications have 
however been made to some of these models and have been proved to be able to describe the 
process when parameters have been determined empirically [110, 115].  A standardised model, 
however, seems to remain elusive, which is evident in the studies of Cabanillas et al. [110] and 
Torrado et al. [115] who each used the same bone cements (CMW1 Gentamicin), but found 
differing best fit models to their measured data.   
 
Due to these differences, and the apparent study specific variability in fitting equations to the 
released concentrations, the concept within this study is to be tested with the Modified Kirby-
Bauer procedure described in Chapter 4.  This test gives direct information regarding the 
colonisation prevention capacity of the concept, from which the duration of released 
concentrations above the therapeutic limit can be deduced.   
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2.2.4.3 Vancomycin 
Vancomycin is a glycopeptide antibiotic obtained from fermenting the bacterial species 
Streptomyces orientalis [117].  It is used in treatment regimens against resistant Gram-positive 
bacterial infections and specifically MRSA infections [118].  Also known as a “drug of last 
resort”, vancomycin is utilised with utmost care and specificity to prevent further development of 
resistance [119]. Vancomycin is distributed for laboratory use in the form of vancomycin 
hydrochloride, a white and odourless powder.  The molecular structure of vancomycin is 
presented in Figure 2.8.  Of particular importance are the aromatic carbon rings and carbonyl 
groups, which enable the molecule to be detected and quantified via UV absorption methods.  
 
 
Figure 2.8: Molecular structure of vancomycin (adapted from [120]) 
 
Selected physicochemical properties of vancomycin are presented in Table 2.6.  Similar to Table 
2.4, the presented molecular weight is only for the vancomycin molecule and exclusive of 
hydrochloric acid.  
 
Table 2.6: Selected properties of vancomycin [85, 120] 
Generic name Empirical 
Formula 
Molecular 
Weight [g/mol] 
Melting 
Point ºC 
Water 
Solubility 
pH (5% solution in 
water) 
Vancomycin C66H75Cl2N9O24 1449.25 185-188 > 100 mg/ml  2.5 - 4.5 
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Vancomycin exerts its antibacterial properties by interfering with the synthesis of peptidoglycan 
(a structural polymer consisting of sugars and amino acids) in the cell walls of Gram-positive 
bacteria.  It specifically binds to the D-alanyl-D-alanine termini where it prevents cross linking of 
peptidoglycan monomers, which significantly weakens the cell wall and results in bacterial death 
through lysis [117, 121].  The relative large molecular mass of vancomycin prevents it from 
crossing the outer layer (consisting of phospholipids, proteins and lipopolysaccharides) of the 
Gram-negative bacterium and is therefore inactive against it [117, 118].  The antibacterial 
spectrum of vancomycin is presented in Table 2.7.  Since vancomycin is only used as a last resort 
and only against certain pathogens, Gram-positive bacteria typically treated with less severe 
antibiotics are omitted from Table 2.7 to maintain relevance to vancomycin application  
 
Table 2.7: Gram-positive antibacterial spectrum of vancomycin [122, 123] 
Susceptible Resistant Intrinsically Resistant 
MRSA VRSA Leuconostoc 
MRSE VISA Pediococcus 
PRSP VRE Lactobacillus 
VSE  Erysipelothrix  
MRSE – Methicillin resistant Staphylococcus epidermidis; PRSP – Penicillin resistant 
Streptococcus pneumoniae; VSE – Vancomycin susceptible enterococci; VRSA – Vancomycin 
resistant Staphylococcus aureus; VISA – Vancomycin intermediate Staphylococcus aureus; VRE 
– Vancomycin resistant enterococci 
 
For the purpose of this project, however, the main interest is its activity against MRSA.  The MIC 
for vancomycin of MRSA is 2 µg/ml for 90% of tested isolates.  The antibacterial activity of 
vancomycin is reported to be maximised at a concentration to MIC ratio of four [117].  This 
means that ideally the concentration of vancomycin at the infected site should not drop below 8 
µg/ml but should also not reach levels that will evoke systemic toxicity.  Currently, vancomycin 
is mainly administered intravenously with a dose of 1 g over 12 hours.  Adverse effects include 
red man syndrome due to overproduction of histamine in the body upon too rapid infusion.  The 
main toxic effects include possible nephrotoxicity at serum levels greater than 30 µg/ml and 
ototoxicity at concentrations greater than 50 µg/ml.   
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2.2.4.4 Local Controlled Vancomycin Release 
The ultimate goal of controlled drug delivery is to “deliver the therapeutic dose of the drug to the 
site in need for the necessary amount of time” [124].  Controlled drug delivery differs from 
conventional medications (such as oral tablets) in the sense that instead of only controlling the 
total mass of the drug to administer, the rate of drug delivery is also controlled.  The concept of 
controlled release versus conventional release is graphically presented in Figure 2.9 as a generic 
plot of drug concentration at the target site over time.  It illustrates the cyclic fluctuating levels of 
drug concentration after each dosing time of conventional administration [125].  When the 
difference between minimum effective and toxic concentrations is small, conventional release has 
an increased risk of leading to both detrimental situations during the dosage cycle, also presented 
in Figure 2.9.  Controlled release, on the other hand strives to ensure that the therapeutic effective 
concentration is quickly reached, and then maintained for an extended period. 
 
 
Figure 2.9: Generic drug release curve indicating the difference between conventional and 
controlled release (adapted from [125]) 
 
The therapeutic benefits of controlling the rate of release have been summarised by Baker [125]: 
 
 Problems regarding drug overdosing and underdosing can be avoided 
 High local concentrations can be achieved directly to the site of need without risking 
levels that would prove systemically toxic 
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 The therapeutic efficacy of the drug is improved by avoiding the large fluctuations in 
concentration that is characteristic of oral administering of tablets 
 With controlled delivery, much less quantity of the drug is necessary to achieve the same 
local concentrations as would be with systemic delivery.  
 
The last point has also been confirmed in a study by Young et al. [126]. By comparing 250 and 
500 mg intraosseous bolus injections of vancomycin locally to 1 g of intravenous administration, 
they found much higher concentrations of vancomycin in bone and subcutaneous fat samples for 
both doses delivered locally.  This implies that that the upper boundary is shifted greatly when 
drugs are delivered intraosseously.  Since these high local concentrations of vancomycin did not 
produce systemic values close to the toxic limit, the focus is to maintain a minimum 
concentration higher than 4 times the MIC of MRSA (8 µg/ml). 
 
2.2.4.5 Drug Release through Synthetic Membranes 
Three main drug release profiles for local drug delivery are defined in literature.  They are:  
 
 diffusion according to Fick’s law when the pores allow free movement of molecules, 
 constraint diffusion as the pore size starts to restrict the movement of the molecules, 
 single file diffusion when the pore size is smaller than two times the molecule size [127].  
All three release profiles are therefore governed mostly by the membrane pore- to solute molecule 
size ratio.  The three different models are depicted in Figure 2.10. 
 
 
Figure 2.10: Different diffusion models resulting from the membrane pore to solute 
molecule size ratio (adapted from [127]) 
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An appealing aspect of zero- or near order release is that the release rate of the drug becomes 
more or less constant without any influence from the reservoir drug concentration [128].  Where 
an initial burst release is good for the immediate reduction of bacteria, a sustained, near zero-
order released would provide prolonged drug release for as long as the drug remains stable in the 
employed formulation.  These two effects could also be combined by a bolus injection during one 
stage exchange, supplemented with constraint or single-file diffusion from within the implant 
reservoir to maintain a therapeutic drug concentration at the site of infection. 
 
To empirically evaluate the mechanism of release, Fickian, constraint, or zero-order, the 
Korsmeyer-and-Peppas model can be applied [129, 130].  It accounts for the first 60% release of 
the loaded drug to determine the mechanism of release.  The model is based on the released 
percentage of total loaded drug as follows, 
 
 Mt
M∞
= Ktn (2.1) 
 
where Mt and M∞ are the respective cumulative masses released at time t and infinity, K is the 
release rate constant (units t
-n
) which takes into account geometrical and structural properties of 
the drug and polymer system, and n is the diffusion exponent that defines the mechanism of 
release in the obtained profile.  The intervals and accompanying interpretations of n for release 
from slabs are summarised in Table 2.8.  
 
Table 2.8: Values and accompanying interpretation of diffusion exponent n [129, 130] 
Value of Diffusion Exponent n Diffusion Mechanism 
≤ 0.5 Fickian diffusion 
0.5 < n < 0.1 Anomalous non-Fickian diffusion (constraint release) 
1 Case-II transport (zero-order release) 
>1 Super Case II transport  
 
 
Therefore, if n is smaller or equal to 0.5 the release is controlled by Fickian diffusion alone, 
whereas for n = 1, the mechanism is controlled by relaxation in the polymer matrix.  For n-values 
between the extremes, release occurs through a combination of a possibility of various effects, 
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typically amongst which is considered to be both diffusion and polymer relaxation resulting in a 
pseudo first order, constraint release profile [131]. 
 
For detection of vancomycin, reversed phase high performance liquid chromatography (RP-
HPLC) is specified in the British Pharmacopoeia [132].  It is also the most precise method for 
concentrations in the µg/ml range [133].   
 
2.2.5 Overview of High Performance Liquid Chromatography (HPLC) 
HPLC is a widely used separation method that enables both the identification and quantification 
of different solutes within a solution or dispersion, in this case vancomycin.  The process enables 
a sample solution containing vancomycin to be separated by passing it through a chromatographic 
bed, also referred to as the stationary phase.  The medium which transports the sample through 
the solid phase is termed the mobile phase [134].   
 
2.2.5.1  Process Apparatus 
The fundamental components of an HPLC system are presented in Figure 2.11.  Meyer lists these 
as the “solvent reservoir(s), transfer line with frit, high-pressure pump, sample injection device, 
column, detector, and data acquisition” [134].   
 
 
Figure 2.11: Simplified schematic of HPLC apparatus a) solvent reservoir, b) transfer line 
with frit, c) high pressure pump, d) sample injector, e) column, f) detector, g) waste, h) data 
acquisition and processing (adapted from [134]) 
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In Figure 2.11 the mobile phase is contained in the solvent reservoir(s), which is transported 
through the transfer lines by means of a high-pressure pump.  The sample injector then injects a 
specific volume of sample in to the mobile phase and is transported to the chromatographic 
column, where the separation takes place.  Solutes elute at different retention times depending on 
their properties and are then transported to the detector before they exit the system through the 
waste transfer line.  The signal from the detector is continuously fed to the data acquisition unit 
throughout the process where it is analysed. 
 
A wide range of system components exists, the details of which each are applied to a variety of 
scientific fields and therefore, this section is limited to the configuration utilised in this project.  
This is the application of reversed phase HPLC (RP-HPLC) for vancomycin quantification by 
means of ultraviolet-visible light (UV-vis) detection.   
 
2.2.5.2 Reversed-phase High Performance Liquid Chromatography (RP-HPLC) 
RP-HPLC is regularly applied for the analysis of pharmaceuticals.  It describes the 
chromatographic process in which the mobile phase is more polar than the stationary phase, and 
in which the stationary phase is hydrophobic [134, 135].  The hydrophobicity is due to the surface 
modification of normal silica with n-alkyl silanes, most notably those with 18 carbons, C18 [135].  
Solutes elute at different rates through the column according to their degree of hydrophobicity 
and polarity [136].  Water is the weakest eluent in RP-HPLC, allowing the direct injection of 
samples with the only required pre-treatment being centrifugation or filtration.  The “strength” of 
the interaction between solute and stationary phase requires the use of organic solvents to 
transport solutes through the column to the detector [134]. 
 
2.2.5.3 UV-Vis Absorbance Detection  
UV-Vis detectors are among the most common used detectors.  These detectors are stable during 
small changes in temperature and also exhibits linearity in their detection (signal value is linearly 
proportionate to the concentration of solute).  Molecules for UV detection need to contain 
chromophores [134].  When the vancomycin passes the detector, it records the variations in 
concentration within the mobile phase as deviations from the baseline and outputs it as an 
electrical signal to the interface software where it is graphically displayed as a chromatogram.  
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2.2.5.4 Chromatogram 
The signals from the detector are displayed as Gaussian curves, also termed peaks.  A 
chromatogram is the complete set of peaks recorded during the entire analysis period of the 
sample [134].  A generic simplified chromatogram revealing the presence of two distinct solutes 
is presented in Figure 2.12.  
 
 
Figure 2.12: Simplified representation of a chromatogram with two solutes [137] 
 
The elapsed time between sample injection and detection of the compound of interest is known as 
the retention time, tr, for that compound.  In Figure 2.12 the retention times of the two compounds 
are denoted as tr,1 and tr,2 respectively, whereas t0 represents the retention time for a solute that is 
not retained in the system.  Total absorbance for a compound is obtained by the integral across 
the base width of its peak, denoted by tσ,1 and tσ,2 for two arbitrary analytes in Figure 2.12.   
 
2.2.5.5 Quantification of Vancomycin Concentration 
For quantification it is necessary to first establish a calibration curve for the specific analyte and 
method in use.  This is done by analysing the absorbance of the drug in injection volumes from a 
specific predetermined dilution series of the antimicrobial and fitting a straight line to the dataset 
with simple linear regression analysis (absorbance on the y-axis as the response variable and 
concentration on the x-axis).  The concentrations of drug eluted from the implant samples are 
then determined by substituting y in the resulting linear regression model with the measured 
absorbance to find the corresponding value for x, the concentration. 
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2.3 Additive Manufacturing 
Modern layer AM technologies are based on the paradigm developed in the late 1980’s with the 
well-known liquid based stereolithography (SLA), a cornerstone of Rapid Prototyping (RP) 
technologies [138, 139].  Initially they were mainly utilised for creating parts for visualisation 
purposes only, but in recent years, RP has evolved into technologies that allow the manufacturing 
of functional parts.  These technologies are today collectively referred to as AM [140].  
Therefore, metal powder based AM technology entails the fabrication of functional products in a 
layer-by-layer addition of material approach instead of the conventional subtractive processes 
during which a product is machined or cut from a larger volume of stock material [141].  
Consequently, this enables the manufacturing of a wide variety of unusual and intricate 
geometries, leaving the designer with much more freedom and possibilities than with 
conventional design for manufacture [142].  AM technologies are especially of interest in the 
aerospace and biomedical sectors.  The process in total also seems to bear significant economic 
advantages, since conventional manufacturing by subtractive processes during which great 
percentages of the bulk material goes to waste, can be very expensive and time consuming in 
comparison to AM [143, 144].   
 
Cronskär et al. [143] determined that, under suitable circumstances, a cost reduction of 35% can 
be achieved for the manufacture of femoral hip stems with AM (EBM) in comparison to 
conventional manufacturing.  Similarly, Dehoff et al. [144] published that AM technologies pose 
the opportunity to reduce the manufacturing cost by more than 50% for a thin walled aerospace 
bracket.   
 
A generic process chain of the basic steps applicable to nearly all AM processes is presented and 
each of the different steps in the process chain is discussed.  In order to gain an understanding of 
the paradigms and underlying concepts of AM, it is necessary to present an overview of the 
different technologies as is applicable to the eventual development of metallic powder bed fusion.  
Due to the large variety of AM technologies on the market, the scope of the discussion on AM 
has been shifted in order to maintain relevance to the main theme of the study.  With the 
exception of stereolithography (SLA), the focus is placed on the technologies in which a layer of 
powder is distributed over a building table and cured or fused according to a specified layer 
thickness (slice) of the cross sectional geometry of the 3D CAD input file. 
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2.3.1 Generic Additive Manufacturing Process Chain 
The different AM processes each exhibit certain specific technical characteristics in terms of the 
actual machines that distinguish them from each other.  In the process of part creation, however, 
many similarities exist between most of the processes.  Therefore, a general process chain can be 
presented to apply to most, if not all, AM processes. 
 
The process primarily consist of the following five steps, Standard Triangulation Language (STL) 
file generation, file verification and repair, build file creation, part construction, and part cleaning 
and finishing [145].  Although it is argued that 3D CAD modeling of the part is not inherently 
part of the actual AM process, it is included in the generic process chain diagram of Figure 2.13 
because all digital manufacturing parts have to start with the CAD modeling thereof.  The CAD 
model is of importance since it is the input data to the AM manufacturing process, and as with all 
processes, the quality of the output is directly linked to the quality of the input data.    
 
 
Figure 2.13: Generic AM process chain  
 
Figure 2.13 shows the first step after creating a satisfying CAD model to be the generation of an 
Standard Triangulation Language (STL) file, which is a neutral file format utilised for AM.  All 
commercial CAD software packages have the ability to export the part to STL format, but not all 
produce STL files with the same accuracy and quality.  It is an important factor to consider when 
selecting the software package.  An STL file is a mesh of triangles that approximates the 
geometry of the part.  The file can be exported in either binary or ASCII format and consist of all 
the coordinates of the vertices of the triangles which collectively approximate the original 3D 
CAD model [145].  An example of this concept is presented in Figure 2.14, with the original 3D 
CAD model on the left and the exported STL approximation of the original model on the right.   
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Figure 2.14: 3D CAD model on the left with STL approximation on the right 
      
Once an STL file has been generated it needs to be verified and repaired if any defects are 
present.  Common triangulation defects can typically be overlapping triangles, near flat triangles 
and non-coincident triangles [145].  To ensure a valid file, two vertices must be shared by 
adjacent triangles and the direction of surface normals must be outward.  Although commercial 
software packages such as Magics (Materialise) have STL repair and refining toolsets, in some 
cases it can be necessary to revise the CAD model in order to ensure a functional STL part for the 
AM process. 
 
The next step is the creation of the build file, which encompass some sub-steps and concepts to 
regard.  The first is part orientation.  Due to the layer-by-layer nature of AM, all parts will 
inherently have ‘stair-stepping’ (Figure 2.15) with the exception if all features are completely 
vertical or horizontal [146].  This effect can be minimised with decreasing layer thicknesses, 
which in turn will lead to more layers and an increase in build time.  It is therefore important to 
decide upon this trade-off in preparing the build file. 
 
 
Figure 2.15: Representation of the stair stepping effect due to slicing for finite layer 
approximation of the original CAD geometry (adapted from [145]) 
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Another aspect to consider is whether or not support structures are needed.  Support structures 
provide a means of attachment for the part to the base plate, ensure that any overhanging 
geometries are kept in place and also contributes to heat dissipation during the build process.  
These structures can also be placed within part features to assure proper support for the structure 
in order to warrant for geometrical accuracy.  It is important to keep in mind that these structures 
need to be removed after the built, typically with aggressive mechanical processes such as manual 
removal or machining, and should be specified so as to not cause any damage to the part surface 
during removal.  Figure 2.16 shows the support structures utilised for building cylinders on an M2 
cusing system.  The supports can be removed manually by chiselling them away from the part 
surface or by wire cutting if they are more bulky.   
 
 
Figure 2.16: Support structures for attaching cylindrical parts to the build plate of a 
Concept Laser M2 cusing machine 
 
The next step is to decide on the layers, ‘slicing’, of the part according to available range of layer 
thicknesses permissible by the AM system in question.  Each slice includes the cross sectional 
two dimensional geometry of a specific height of the part.  This is in essence the X-Y tool path in 
which the control system guides the laser (or other system for creating layers) to create each layer 
[145].  As mentioned with regard to the stair effect, an appropriate trade-off must be made 
between build time and part integrity when selecting the slice or layer thickness. 
 
The part placement on the build plate can now be specified and the build file created.  In 
compiling the build file, parameter selection is very important.  Many AM systems have default 
processing parameters as specified by the manufacturer, but varying these parameters can near 
optimise the process to the specific user’s needs [147].  Two of the main parameters are laser 
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power and laser travel velocity (scanning speed), but different AM processes inherently have 
different parameters that can be varied.  When the build file is created it is sent to the machine 
control software to begin the build.    
   
Parts are built from the bottom up, one slice at a time.  Once the part is finished it can be removed 
from the machine, support structures removed and cleaned.  Some parts require post processing 
such as wax or bronze infiltration in order to ensure better structural integrity.  Other processes 
can be sand-blasting, grinding or polishing, but the important point is that the operator should 
identify and thoroughly execute the necessary post processes to ensure functionality and 
applicability of the part for its intended use.  An overview of selected relevant AM processes is 
presented in the following sections.    
 
2.3.2 Additive Manufacturing Technologies 
2.3.2.1 Stereolithography  
SLA is a liquid based AM process commercialised by 3D Systems in 1987, and is argued to be 
one of the fundamental technologies developed with an additive based paradigm [139].  A 
photosensitive polymeric resin is selectively scanned and cured by a stationary ultraviolet (UV) 
laser which is directed by scanning mirrors according to two dimensional, X-Y plane, cross 
sectional slices from a 3D CAD model [145].  The energy from the UV laser penetrates into the 
photopolymer and causes it to solidify.  Figure 2.17 displays a simplified schema of the process. 
 
 
Figure 2.17: Schematic representation of the SLA process (adapted from [148]) 
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After the cross section in question has been fully scanned by the UV laser, the build platform 
lowers in the Z-direction into the resin by the preset layer thickness, typically 100 µm [139].  A 
coating blade then ensures the even dispersal of a fresh layer of resin onto the build platform after 
which the next cross section is scanned and cured.  This process is repeated until all the slices are 
completed and the 3D part is finished.  All parts produced by SLA are placed in either a thermal 
or UV oven in order to ensure that any uncured resin is cured. 
 
2.3.2.2 Three Dimensional Printing  
The three dimensional printing (3DP) process, as currently commercialised by Z Corporation, 
originated out of research conducted at the Massachusetts Institute of Technology (MIT) in the 
early 1990s [149].  A process called drop-on-demand jetting technology, which closely resembles 
that of inkjet printing, selectively delivers droplets of binder fluid onto a powder bed.  The binder 
then solidifies, creating the X-Y cross sectional geometry of the 3D CAD model in question [145].  
A simplified schema of the process is presented in Figure 2.18. 
 
 
 
Figure 2.18: Schematic representation of the 3D Printing process (adapted from [139]) 
 
At the start of the build, the build station module lowers by the preset layer thickness which is 
typically in the region of 0.080 – 0.250 mm [150].  The powder delivery module rises to supply a 
fresh layer of powder which is evenly spread over the build chamber by a roller.  A modified 
inkjet print head selectively traverse the powder bed, delivering binder droplets onto the profile of 
the layer in question.  This process is repeated until all the layers, and consequently, the part is 
finished.  Adequate time is then given for the binder to dry and harden before the part is extracted 
[145].  To add structural stability to the part, it can be infiltrated with various epoxies or wax 
material as part of post-processing [151]. 
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2.3.2.3 Selective Laser Sintering  
Selective laser sintering (SLS) was first patented by Ross Householder in 1979, but the process 
was only commercialised in the late 1980’s as a result of development work at the University of 
Austin in Texas [139].  Similarly to 3D Printing, SLS produces three dimensional parts in a 
layered fashion.  The SLS process, however, is capable of processing polymers, polymer coated- 
ceramics and metals.  A simplified schema of the process is presented in Figure 2.19.   
 
 
Figure 2.19: Schematic representation of the SLS process (adapted from [139]) 
 
Thermal energy supplied by a carbon dioxide (CO2) laser is used to fuse powder particles together 
within a highly controlled environment.  A system of scanning mirrors controls the focal points of 
the laser and guides it to selectively traverse the powder bed in order to fuse together the 2D 
profile of the layer in question.  The build station then lowers by the preset layer thickness 
(typically 0.020 – 0.15 mm) and a powder coating roller evenly spreads a fresh layer of material 
before the next layer profile is scanned [152].  This process repeats until the full 3D CAD model 
is built.  The powder is preheated inside the build chamber to just below the sintering temperature 
of the working material.  This reduces the otherwise high thermal gradients between the non-
sintered and sintered powder particles.  Non-sintered powder particles serve as supports for the 
part.  After build completion, the build station rises and the chamber needs to cool down 
uniformly before the part can be removed [145].  Metal parts however, are not fully dense after 
processing, and are similar to powder metallurgy parts in the green state.  Post processing in a 
furnace is necessary to burn away the polymer coating, followed by bronze infiltration to 
complete the metallic part [139].      
Inert atmosphere 
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2.3.2.4 Electron Beam Melting  
In contrast to 3D Printing and SLS, fully functional and nearly fully (> 99%) dense metallic parts 
can be created through EBM without the need for additional binder materials [153, 154].  An 
electron beam in a vacuum is utilised to melt the metal powders layer-by-layer [142].  A 
simplified schema of the EBM process is presented in Figure 2.20.  
 
 
Figure 2.20: Schematic representation of the EBM process (adapted from [142]) 
 
In EBM, an electron gun supplies a focused electron beam.  This is achieved through the emission 
of electrons when heating a tungsten filament in excess of 2500°C and the acceleration of these 
electrons by means of a high voltage difference [153].  The nominal operating voltage for the 
electron gun is 60 kV.  The electron beam is positioned and controlled by the deflection coils in 
order to scan and melt the powder on a preheated table in order to fuse and create the specific 
slice in question [142].  Layer thicknesses for EBM can typically vary between 0.05 to 0.2 mm 
[153].   
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Energy for fusing the metal powder stems from the heat generated from loss in kinetic energy as 
the electrons crash into the metal powder [153].  Once a layer is completely scanned, the build 
table lowers by the layer thickness and a fresh supply of powder is deposited from the powder 
depots.  A powder coating blade then moves across the build table to ensure an even spread of 
powder.  The layer in question is again scanned by the electron beam and the process repeats for 
all layers until the part is complete.  The whole build process is executed in a vacuum [142]. 
 
Depending on the needs and requirements of the intended use, various post processing operations 
can be performed on EBM parts.  These can typically include, amongst others, both machining 
and heat treatment processes such as drilling, high speed milling, annealing [155]  and hot 
isostatic pressing (HIP) [156].   
 
2.3.2.5 Selective Laser Melting  
Selective laser melting  (SLM) is a relatively young manufacturing technology through which 
complex three dimensional near net shape metallic parts can be produced in a layer-by-layer 
approach [157].  During this process, thermal energy from a focused fiber laser beam is utilised to 
selectively scan, melt, and fully fuse metallic powder particles on a powder bed, creating near full 
density (> 99%) parts [158, 159].  In house studies have reported an achievable part density of up 
to 99.81 ± 0.1% for SLM processed Ti-6Al-4V ELI [160].  Figure 2.21 shows a simplified 
schema of the SLM process.   
 
 
Figure 2.21: Schematic representation of the SLM process (adapted from [161]) 
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The SLM process itself, utilises the same sequence as SLS for the basic principles of the layer 
wise, bottom-up building process (Figure 2.19), but in SLM, however, full melting of the metal 
powder is the goal [152].  This is achieved by heating the metal powder to beyond its melting 
temperature, in order to secure the full consolidation of the powder for creating the geometry of 
the two dimensional layer in question.  The build platform then lowers by the preset layer 
thickness (typically 30 to 70 µm) [161].  A fresh layer of powder is deposited and evenly spread 
by the coating blade after which the next layer is scanned until all layers are consolidated and the 
part completed.  An attractive characteristic of SLM is that the unused powder can be recycled 
and used in future builds [162].  
 
To avoid oxidation of the metals, SLM needs a controlled, inert environment.  This is achieved by 
flooding the build chamber with Nitrogen or Argon gas, depending on the metal alloy powder 
used.  By doing so, the Oxygen content in the build atmosphere can be reduced to below 0.1% 
[146].   
 
Post processing includes the removal of support structures, usually by mechanical means such as 
machining or manual chiselling (Figure 2.16).  Depending on the specified requirements and 
intended application of the parts, further machining can be necessary in order to reduce surface 
roughness and heat treatment to tailor the microstructure and further reduce porosity [162, 163]. 
 
For the remainder of the document, the SLM process shall be referred to by the specific 
technology utilised in the study, which is the Concept Laser proprietary LaserCUSING
®
.  The 
name stems from combining the words ‘fusing’ with the ‘C’ from ‘Concept Laser’ [164].  More 
specifics regarding to this process are discussed in Chapter 3 with accordance to manufacturing of 
the samples. 
 
From Table 2.2 it was evident that a very significant percentage of the current commercial 
cementless stems are made from the Ti-6Al-4V alloy.  Therefore, a Concept Laser Ti-6Al-4V ELI 
powder alloy is to be used for manufacturing of the samples.   
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2.3.3 Ti-6Al-4V ELI Powder 
Grade 23 Ti-6Al-4V ELI is a material widely used for the manufacture of medical implants and 
devices.  The acronym ELI stands for Extra Low Interstitial and it refers to a reduction in 
specified amounts of interstitial impurities in the lattice structure, specifically with regard to 
elements such as Iron (Fe), Carbon (C), and Oxygen (O) than the well known Grade 5 Ti-6Al-4V 
[142].  In this section the composition and some of the mechanical properties, as is applicable to 
the respective international standards on femoral stems, of the material are reviewed.   
 
The international standard specifications for the chemical composition of Ti-6Al-4V ELI powder 
for powder bed fusion manufacturing processes is published by ASTM with designation F3001-
13 [165].  The specified composition is presented in Table 2.9.    
 
Table 2.9: ASTM standard specification for the composition of Ti-6Al-4V ELI for Powder 
Bed Fusion [165] 
Element min max 
Aluminium 5.50 6.50 
Vanadium 3.50 4.50 
Iron ... 0.25 
Oxygen ... 0.13 
Carbon ... 0.08 
Nitrogen ... 0.05 
Hydrogen ... 0.012 
Yttrium ... 0.005 
Other elements, each ... 0.10 
Other elements, total ... 0.40 
Titanium remainder remainder 
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2.4 Concluding Remarks  
This chapter presented an integrated review of the different disciplines encompassed within the 
focus of the study.  Some of the research sub-questions have also been addressed.  These include 
the pathogenesis and mechanisms of chronic PJIs, some of the clinically approved drugs and 
commercially approved drug delivery products, and the positioning of the current study within the 
larger field of infection prevention strategies.   
 
The multidisciplinary nature of the project is also evident, concerning medical, microbiological, 
pharmaceutical and additive manufacturing sciences.  Combining elements from these sciences 
towards evaluating a new concept for infection prevention and treatment in cementless femoral 
hip stems is central to this study.  It is especially important since a product, service or strategy 
cannot be developed without proper knowledge regarding the extent, conditions and 
environments surrounding its intended use.  The relationships between the disciplines are 
summarised below in Figure 2.22. 
 
 
Figure 2.22: Schematic of interdisciplinary relationships 
 
Further interactions within these relationships are also apparent in the remaining chapters during 
which the additive manufacturing and testing of the concept are evaluated and discussed. 
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3. Fabrication of Drug Delivery Samples 
This chapter presents the establishment of the samples and conceptual features together with the 
manufacturing thereof samples by LaserCUSING
®
.  The AM process chain as discussed in 
Section 2.3.1 was applied throughout the manufacturing phase.  
 
3.1 Establishment of Conceptual Features 
For the design of these conceptual features, different zone of inhibition (ZOI) studies, which all 
included Palacos R+G, were used as guidelines and are summarised in Table 3.1.  ZOI values 
have been converted to area for application to the current study, with the zone widths of the 
respective studies in parentheses.  It is important to note that the reported results are specific to 
the conditions present in each respective laboratory which cause variability.   
 
Table 3.1: Reference studies on Palacos R+G ZOI testing 
Reference 
Disc Dimensions 
(Ø x h) [mm] 
Disc Surface 
Area [mm
2
] 
S.aureus Strain 
ZOI after 24 hours 
[mm
2
] (width [mm]) 
Ensing et al [108] 6.0 x 3.0 113.10 7323 ≥ 587.48 (11.0) 
Meyer et al. [166] 9.6 x 3.25 242.78 ATCC 6538P 500.17 (8.7) 
Miola et al. [167] 10.0 x 5.0 314.16 ATCC 29213 776.76 (13.5) 
Thompson et al. [168] 9.7 x 3.3 248.36 ATCC 6538P 469.36 (8.3) 
Ferraris et al. [169] 10.0 x 4.0 282.74 ATCC 29213 628.32 (10.0) 
 
It was deduced from Table 3.1 that the size range of the discs tested did not have a large effect on 
the antibacterial efficacy.  One would have to scrutinise the details and differences in mixing 
techniques, elution protocols, environmental conditions and S.aureus strains to better account for 
the variability, which was not the purpose here.  Rather, the features to utilise in this study should 
be based on dimensions that would typically fit into an actual femoral stem.  To this extent, the 
most suitable geometry for analogy and subsequent incorporation was found in the study by 
Ensing et al. [108] who reported on the antimicrobial efficacy of discs with 6mm diameter and 
3mm thickness.  Based on this, a revised concept model to the one in Figure 1.1 was developed.  
The main feature from the concept model was isolated for samples to be manufactured.  This 
process is depicted in Figure 3.1.   
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Figure 3.1: Isolation of main conceptual feature from the larger stem 
 
The extracted samples are 15 mm by 15 mm by 12 mm with 3.5 mm diameter internal channels 
centred on and perpendicular to each of the six surfaces.  These details regarding the sample are 
presented in Figure 3.2.  Since the burst effect of ALBC elution is mainly a surface phenomenon, 
each channel opens at the surface of the sample with a 6mm diameter by 2mm deep disc 
geometry to avail a larger surface area for gentamicin elution [41].   
 
Channel openings of these dimensions enable the possibility for expected results.  Since Palacos 
R+G is a highly standardised product, the ZOI should be at least 587.48 mm
2
 after 24 hours, but 
is expected to be greater due to the higher amount of gentamicin that should release in the burst 
phase because of the six release surfaces in the concept instead of only one as in the literature.  
 
Towards maintaining a conservative design, the size of the sample had to be such that the 
bacterial growth boundary of the lower limit of the widths of ZOIs reported by Ensing et al. [108] 
after 24 hours (11 mm) would not traverse any of the edges.  This is shown in Figure 3.3.  In a 
full scale prototype the channel openings should also be spaced such that the entire surface area 
between the openings would be accounted for in preventing bacterial colonisation.  
 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 3                               Industrial Engineering 
   Page 49 
 
 
Figure 3.2: Detailed drawing of the samples with the conceptual features 
 
 
Figure 3.3: Sample size in relation to a reported lower limit of ZOI width of 11 mm after 24 
hours from Palacos R+G discs with similar dimensions 
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3.2 Manufacture of Samples 
All samples were manufactured on the Concept Laser M2 cusing system (Figure 3.4) from Ti-
6Al-4V ELI powder (Concept Laser designation CL 41TI ELI).  The powder has a rated particle 
size distribution of 38 µm to 55 µm and is specified by Concept Laser to meet the ASTM 
requirements  
 
 
Figure 3.4: Concept Laser M2 cusing system 
 
Conceptual 3D models were developed in Inventor Professional 2011 (Autodesk) and exported as 
a STL file with the built in STL generator.  The file was imported into Magics 15.0 (Materialise) 
for pre-processing and build file creation.  The STL file was generated accurately and no errors 
were present that needed repair.  Part orientation was set directly on the build plate at an angle of 
45 degrees to reduce the number of channels that would have to be built parallel to the build plate.  
No support structures were necessary within the channels as they are all less than 8 mm in 
diameter as specified in the machine manual.  The build file was created with a slice thickness of 
30 µm.  The build file was loaded onto the machine software for part placement and process 
parameter selection. Parts were placed at an angle towards the coating blade to ensure an even 
spread of powder over the geometry of each two dimensional slice.  Figure 3.5 a) shows the 45° 
orientation of the samples towards the horizontal and Figure 3.5 b) shows the part angled towards 
the coating direction which is indicated with the black arrow.   
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               (a)      (b) 
Figure 3.5: Manufactured samples on build plate with a) revealing the 45° part orientation 
towards the horizontal and b) the angular orientation of the parts towards the coating 
direction of the powder coating blade, indicated by the arrow (parts other than the 
reservoir samples were built for a different study) 
 
Default processing parameters for Ti-6Al-4V ELI were used for LaserCUSING
®
 of the samples.  
These parameters are 100 W laser power, 600 mm/s scanning speed, and 30 µm layer thickness, 
were used for the processing of the samples.  A screen shot of the parameters are presented in 
Figure 3.6.   
 
The layers of powder are scanned by the laser in 5 mm x 5 mm islands oriented perpendicular to 
each other.  The hatching pattern is set to single vectors parallel to one another inside the island 
with spacing between the vectors (indicated as ‘a1’ in the ‘fill vectors exposure’ section of Figure 
3.6) fixed at 0.7 of the laser diameter (150 µm).  This implies that each of the molten tracks inside 
the islands overlap with 45 µm to enhance full melting of the powder during the process.  There is 
also a scanning overlap between the islands of 0.15 times the laser diameter, designated as ‘a2’ in 
the ‘fill vectors exposure’ section of Figure 3.6.  The outer geometry of each layer has a contour 
scan along its edge before a new layer of power is coated. 
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Figure 3.6: Screen capture of process parameters used for LaserCUSING
®
 of samples 
 
3.3 Post-processing of Samples 
Samples were removed from the build plate by third party wire-cutting and numbered in a random 
order upon return from third party removal.  Unconsolidated powder particles were manually 
removed by blasting the samples with a pressurised air gun. 
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4. Pilot Study for Prophylaxis 
The aim of the pilot study was to evaluate the feasibility of the concept for colonisation 
prevention through antimicrobial elution from a commercial ALBC embedded within the surface 
of Ti-6Al-4V samples manufactured by LaserCUSING
®
.  Another aspect also investigated was 
whether Palacos R+G could be used as a type of permeable material when mixed by hand without 
the application of specialised mixing and preparation techniques. 
 
4.1 Mixing and Introduction of Antibiotic Loaded Bone Cement (ALBC) 
The commercial ALBC, Palacos R+G loaded with 12.5mg/g gentamicin, was prepared under 
atmospheric pressure as per manufacturer’s instructions in a monomer-to-polymer ratio of 1 ml to 
2 g [170].  With a density for MMA of 0.94 g/cm
3
, a 1 ml (or 1 cm
3
) to 2 g ratio yields a polymer 
proportion of PPolymer= 2 2.94⁄  =0.68027.  The parts were mixed in an Eppendorf tube with a 
spatula for 30 seconds until cement became doughy and was left for one minute.  The mixed 
cement was then used to manually fill the channels of the samples during the application phase of 
the cement.  The ALBC was left to set inside the samples.  Protruding cement was filed down 
with a sterilised file.  
 
The mass of Palacos R+G loaded into each of the samples, MPalacos R+G, was determined by 
averaging the mass of each sample weighed five times on an analytical balance (Sartorius 
BP110S) before and after Palacos R+G introduction and subtracting the initial mass from the 
mass after loading.  The mass of gentamicin loaded into each sample, Mgentamicin , was then 
theoretically approximated by multiplying the mass of Palacos R+G by the constituent polymer 
proportion, PPolymer, and then with the gentamicin proportion, PGentamicin, contained within the 
polymer powder.  It is shown below in Equation 4.1 in which the values for the polymer and 
gentamicin proportions are 0.68027 and 0.0125 respectively. 
 
 Mgentamicin= MPalacos R+G × PPolymer × PGentamicin (4.1) 
 
The eventual aim is to create a drug delivery scenario that enables the possibility for utilising the 
channels as a reservoir from which drugs can be administered.  To this extent, an appropriate 
permeable material is necessary to close off the openings of the channels.  PMMA is known to be 
hydrophobic, but aqueous fluids can penetrate into the cement through imperfections in the 
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polymer matrix such as cracks and voids [41].  The challenge, however, is to obtain an 
interconnected porosity that would allow fluids to move through the polymer matrix.   
 
To investigate the effect of monomer-to-polymer mixing ratio on the PMMA porosity, three bone 
cement cylinders for each of three different monomer-to-polymer volume [ml] to weight [g] ratios 
(1:2; 1:1.5; 1:1)  were made and CT-scanned (General Electric Phoenix VTOMEX L240) at a 10 
µm resolution.  CT-scans were analysed by the CT-scan group for porosity with VGStudio Max 
2.1 (Volume Graphics).  The graphical analyses were reviewed and the solid parts of the material 
removed with myVGL 2.2 (Volume Graphics), which is a viewer only version of the VGStudio 
software.  The application of ALBC in this study is purely for drug delivery and serves no 
function in fixation, and therefore, the effects of monomer-to-polymer mixing ratios on the 
mechanical properties are not relevant.       
 
4.2 t- Test Statistics 
To evaluate the significance of different porosity percentages for the varied monomer-to-polymer 
mixing ratios, two-tailed Student t-tests (assumed equal variances) for independent samples were 
performed.  The sample size for each ratio was three and the significance level was α = 0.05 
(reject if p < 0.05).  The null hypothesis was set that the samples are from the same population 
and that there is no significant difference in the resultant porosities.  That is, for each of the three 
comparison combinations: 
 
H0: μ1 = μ2 
H1: μ1 ≠ μ2 
 
Therefore, failing to reject the null hypothesis would mean that the mixing ratios selected have no 
significant influence on the resultant porosity.   
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4.3 Gentamicin Antibacterial Efficacy  
The efficacy of a colonisation prevention strategy for delivering drugs in high enough 
concentrations to thoroughly maintain the bactericidal effect has to be evaluated in order to be 
able to prove that the strategy is a feasible concept.  The initial testing should therefore be 
economic and not resource intensive.  To this extent, a modified Kirby-Bauer disk diffusion 
method is a suitable test to be utilised in a semi-quantitative manner [171].  It allows for 
measuring the area of the zones of bacterial growth inhibition around the biomaterial samples, 
caused by the elution of gentamicin from the ALBC embedded within the samples [166, 172].  
Since this type of test is typically used for determining antibiotic susceptibility of pathogens, it is 
modified in the sense that it is not used to test whether an organism is susceptible, but rather if an 
organism with known susceptibility can be prevented from colonising the biomaterial surface 
[171, 173].  It therefore allows for quantification of bacteria free areas around the biomaterial, as 
well as for the time period that colonisation can be prevented.   By executing this experiment, the 
feasibility of the concept could be evaluated economically and in a relative short time frame.   
 
4.3.1 Modified Kirby-Bauer Diffusion Test 
The preparation and inoculation of S.aureus Xen 36 and S.aureus Xen 31 for antimicrobial testing 
was conducted by A.D. van Staden at the Lactic Acid Bacteria and Antimicrobial Peptide 
Taxonomy Laboratory of the Department of Microbiology at Stellenbosch University.  The text in 
this section is adapted from that of Mr. van Staden as was contributed towards a research paper. 
 
Samples to be loaded with Palacos R+G were sterilized before use by autoclaving at a 
temperature of 121°C and a pressure of 100 kPa for 15 minutes.  The samples were then also 
subjected to short wavelength (254 nm) UV sterilization for 30 minutes.  S.aureus Xen 36 and 
S.aureus Xen 31 (Caliper Life Sciences) were grown in brain-heart infusion (BHI) broth (Biolab, 
Merck) which were supplemented with 200 µg/mL kanamycin (Sigma Aldrich), at 37°C for 24 h.  
Kanamycin is an aminoglycoside antibiotic added to kill possible contaminating bacteria, but 
does not affect either of the S.aureus strains since they are both resistant to kanamycin. 
 
The samples loaded with ALBC were aseptically placed in a Petri dish (150 mm x 25 mm) on top 
of a thin, sterile BHI agar (Biolab, Merck) base that was pre-introduced into the Petri dish.  BHI 
agar seeded with 0.1% (v/v) S. aureus Xen 36 or Xen 31 were used to completely cover the 
samples (Figure 4.1) and incubated at 37°C for 24 h. 
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After incubation, 10 megapixel digital images were taken of the ZOIs to monitor the 
antimicrobial efficacy.  The samples were then aseptically removed, lightly washed with 70% 
ethanol (v/v) and left to dry.   
 
Samples were then transferred to a fresh Petri dish containing a BHI agar base and again 
completely covered with BHI agar seeded with 0.1% volume/volume (v/v) S. aureus Xen 36 or 
Xen 31 and incubated at 37°C for 24 h.  This was continued until no visible zones of inhibition 
were observed around the samples.  The BHI agar base and seeded BHI agar were supplemented 
with 1% weight/volume (w/v) agar to ensure sufficient bacterial growth, 0.001% (w/v) 
cycloheximide (Sigma Aldrich) to avoid fungal contamination and 200 µg/mL kanamycin at each 
time point.  S. aureus Xen 36 and S.aureus Xen 31 were freshly inoculated each day for agar 
diffusion assays.  A control sample without any Palacos R+G was also prepared in the same 
manner.  Samples were done in triplicate and the area of the inhibition zones was measured from 
the images using ImageJ.   
 
 
Figure 4.1: Orientation of samples introduced into the agar inoculated with S.aureus Xen 36 
and S.aureus Xen 31 respectively 
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4.3.2 Zone of Inhibition Measurement 
ImageJ is software developed by the NIH in the USA, and is widely used for image processing 
and analysis.  The results of the measurements from ImageJ were copied to MSExcel where it was 
organised and further processed.  Ten measurements from each of two photographs from the 
bottom view of the Petri dishes were used for calculating the average ZOI per 24 hours interval.  
The measuring process is discussed in more detail in the following sections. 
 
4.3.2.1 Calibration of Scale using Pixels 
Before any measurements can be made it is necessary to calibrate the software according to 
known distances in the image.  It is therefore important that images be taken as perpendicular as 
possible to eliminate discrepancies in lengths resulting from photographic perspective.  This can 
easily be evaluated by measuring more than one known distance in the depth of the photograph 
where the plane of interest is.  The plane of interest was selected to be level with the horizontal 
surface of the sample from the bottom direction of the Petri dish.  Since it is known that the 
sample sides on this surface are each 15 mm, it was used as standard for calibration of the 
software.  The scale was set by using the line selection and drawing a line as accurately as 
possible across the sample and then using the set scale tool to specify the distance for the amount 
of pixels.  Figure 4.2 shows a screen shot of the procedure.  The ruler in the picture only serves as 
a rough guide to give a measure of perspective, but cannot be used for accurate calibration since it 
does lie within the plane of interest. 
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Figure 4.2: Calibration of ImageJ for ZOI measurement 
 
The calibration was first tested by measuring random widths across the surface as well as 
measuring the surface area of the sample.  Only if repeated measurements yielded results very 
close to the theoretical values (15 mm sides and 225 mm
2
 surface area) was the calibration 
deemed sufficient for ZOI measurement.  This is shown in Figure 4.2.  The numbers imposed on 
the lines in Figure 4.3 is for reference to correlate with the measurements in the “Results” 
window except for “C” which denotes the line used for scale calibration.  From the results it can 
be seen that the test measurements are very close to the known values.  Therefore, the average of 
20 measurements for each sample was used to reduce these user-induced inaccuracies which 
cause the measurements to be slightly greater or less than the known theoretical values. 
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Figure 4.3: Test measurements with known distances to ensure satisfactory calibration 
 
4.3.2.2 Image Adjustment for Definition 
The next step was to use the image adjustment tools in order to obtain a visually more clear 
definition of the ZOI borders.  This was especially necessary for the resistant S.aureus Xen 31 
strain to determine whether the samples were reached within 24 hours and it also became 
necessary for the susceptible S.aureus Xen 36 at later times as the released amount of gentamicin 
declined and the bacteria neared the samples.  A typical example of the image adjustment and 
subsequent elucidation of the ZOI is presented in Figure 4.4 with (a) the original and (b) the 
adjusted image.  The adjusted image reveals without doubt the ZOI boundary.  This was 
specifically important to establish whether the bacteria reached the samples.  The example 
presented in Figure 4.4 was also selected to convey this importance.  Only once the images were 
adjusted to clearly identify the ZOIs could the measurements be made.  In either case, the 
measurements were made conservatively.    
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                    (a)        (b) 
Figure 4.4: Elucidation of ZOI boundary through image adjustment in ImageJ with ZOI 
boundary obscured in a) and clearly visible in b) 
 
4.3.2.3 Measuring the ZOI 
The polygon selection tool was used as shown in Figure 4.5 to trace the visible ZOI carefully and 
the complete area within the zone was measured.  Repetitions were made from images cleared of 
previous traced polygons to avoid biased measurements based on the polygonal selection of the 
previous measurement. Furthermore,  since the interest is on the bacteria free area, and when 
bacteria reaches any part of the surface it flags a failure, the theoretical surface area of each 
sample (225 mm
2
) was subtracted from its respective measured ZOI. 
 
 
 
  a)                     b) 
Figure 4.5: ZOI measurement in ImageJ when bacteria free zones were obvious a) and when 
zones became less obvious b) 
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5. Prophylactic Proof of Concept – Results Assessment 
5.1 Antibiotic Loaded Bone Cement Introduced into Samples 
The calculated weight of gentamicin loaded into each sample is shown in Figure 5.1.  Samples 1, 
9, and 16 were used for testing with S.aureus Xen 31 and samples 17, 23, and 25 for S.aureus 
Xen 36.   
 
 
Figure 5.1: Calculated mass of gentamicin loaded into each sample for colonisation 
prevention testing 
 
The minimum amount loaded was 5.522 mg for sample 23 and the maximum 6.346 mg for 
sample 16.  The range is therefore 0.824 mg with mean and standard deviation of the loaded 
gentamicin 5.968 ± 0.3 mg.  This reveals that even though the manual introduction of the bone 
cement was rather unrefined, the amount of gentamicin achieved within each sample does not 
vary much and the samples were reasonably uniformly loaded.  The rest of the manufactured 
titanium alloy drug delivery samples were reserved for reservoir release pilot- and full scale 
experiments. 
 
 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 5                               Industrial Engineering 
   Page 62 
 
5.2 Bone Cement Monomer to Polymer Ratio 
A three dimensional rendering of the CT-scan images from the different monomer-to-polymer 
ratios are presented in Figure 5.2.  From top to bottom the rows represent the mixing ratios 1:1, 
1:1.5, and 1:2 respectively.  From left to right the columns show independent study units within 
each mixing ratio.   
 
 
Figure 5.2: CT-scan images of porosity distributions from different monomer-to-polymer 
mixing ratios, a-c) 1:1, d-f) 1:1.5, g-i) 1:2 
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The solid material was removed from view in Figure 5.2 with the software and the three 
dimensional arrangement of the full collection of detected voids within each study unit is 
presented.  A summary with regard to the resulting porosities for each mixing ratio of the 
independent units is presented in Table 5.1.  From Figure 5.2 and Table 5.1 it would appear that 
the porosity is relatively random distributed throughout the samples and that the mixing ratio does 
not significantly influences the average porosity of the bone cement cylinders. 
 
Table 5.1: Porosity for different monomer-to-polymer (MM-to-PM) ALBC samples 
MM-to-PM Ratio [ml:g] Average Sample Volume 
Scanned [mm3] 
Average Relative Porosity [%] 
1.0:1.0 159.64 2.82 
1.0:1.5 166.20 3.01 
  1.0:2.0* 103.02 2.61 
* This is the standard mixing ratio specified in the manufacturer’s instructions 
 
The t-test output from MSExcel integrated function was compared to a manually calculated t-test 
for each of the comparing groups.  The procedure, as described by Montgomery & Runger [174], 
and MSExcel screenshots are presented in Appendix A.  The Student t-tests, shown in Table 5.2, 
have revealed that there is no evidence to reject the null hypothesis (all study units are from the 
same population, stated in Section 4.2) with extremely large p-values (p = 0.8 for ratios 1:2 and 
1:1.5; p = 0.84 for ratios 1:2 and 1:1; p = 0.89 for ratios 1:1.5 and 1:1).   
 
Table 5.2: t-Test results from comparing porosities 
Ratios Compared t-critical (two-tailed) t-calculated P-value 
1.0:2.0 and 1.0:1.5 2.776 -0.269 0.8 
1.0:2.0 and 1.0:1.0 2.776 -0.217 0.84 
1.0:1.5 and 1.0:1.0 2.776 0.142 0.89 
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Another important aspect that is revealed by the CT-images is that there is very little 
interconnected porosity, and that the pores are mostly isolated, individual defects within the 
polymer matrix.  Figure 5.3 shows a CT scan of a sample loaded with ALBC.  It reveals the lack 
of interconnectivity between the pores.  A detailed investigation into the specifics regarding the 
chemistry of the polymerisation process and elongation phase of the polymer chains could 
possibly elucidate these observations, but falls beyond the scope of this study.  Either way, it 
reveals the inability of this commercial ALBC to act as a membrane without any specialised 
moulds or mixing techniques, such as the addition of chitosan particles which creates voids as it 
diffuses from the matrix.  Therefore nanoporous membranes were investigated for release of 
reinforcement antibiotics from within the sample reservoir.  This is discussed in Chapters 6 and 7. 
 
 
Figure 5.3: CT-scan of a sample loaded with ALBC revealing random and non-
interconnected porosity in the PMMA matrix  
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5.3 Antimicrobial Efficacy 
The test was carried out until no inhibition zones were visible anymore, that is 360 hours for 
S.aureus Xen 36 and 48 hours for S.aureus Xen 31.  Failure to prevent colonisation was however, 
defined for the moment bacteria reached the titanium-alloy surface.  These times were 72-96 
hours for S.aureus Xen 36 and less than 24 hours for the gentamicin resistant S.aureus Xen 31.  
 
Samples were expected to present ZOIs of at least 587.48 mm
2
 after 24 hours (Section 3.1) 
against the gentamicin sensitive S.aureus Xen 36 strain.  The resultant average zone areas are 
presented in Table 5.3 with the accompanying measured data in Appendix B, from where it can 
be seen that this has been achieved. 
 
Table 5.3: ZOI [mm
2
] for samples challenged with S.aureus Xen 36 
 Time [Hours] 
 24 48 72 96 
Sample 17 693.15 258.70 239.83 161.30 
Sample 23 784.04 254.07 330.48 201.41 
Sample 25 695.48 240.00 169.50 122.81 
Mean ± SD
a
 724.22 ± 51.82 250.92 ± 9.74 246.60 ± 80.70 161.84 ± 39.30 
a
 SD denotes Standard Deviation 
 
Images of the collective view of the ZOI after 24, 48, 72, and 96 hours for these three samples are 
presented in Figure 5.4, in which the zones are clearly visible around the samples.  The high 
reduction in zone areas from 24 to 48 hours is typical for the burst release of these cements.  This 
observation can be made based on the transferral to a new Petri dish, replacement of the entire 
agar volume and a fresh inoculation of S.aureus Xen 36 after each 24 hour interval, thereby 
removing traces of gentamicin that was released from the embedded Palacos R+G during that 
interval before the next 24 hour period.  Sustained release at lower concentrations can be 
witnessed for the rest of the periods, with the concentrations declining to below effective 
inhibitory concentrations towards 96 hours.  Bacteria reached sample 25 after 72 hours and all the 
samples after 96 hours.  One specific reason for this was not identified, but rather a multitude of 
factors can play a role such as the positioning of the antibiotic crystals within the bone cement 
matrix, the formation or lack of cracks and voids through which the dissolution medium could 
penetrate the cement, the growth rate of bacteria in the specific vicinity of the sample and even 
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possible convective elements transporting bacteria towards the sample.  When zones became 
visually obscure, as with Figures 5.4 c) and d), images were further adjusted to unveil whether the 
surfaces have been reached 
 
 
 
Figure 5.4: Collective view of ZOI against S.aureus Xen 36 after a) 24 hours b) 48 hours c) 
72 hours and d) 96 hours 
 
The effect of adjusting the images with ImageJ can be seen in Figure 5.5.  For example, in Figure 
5.4 (d) it is difficult to distinguish whether sample 23 (bottom left sample in the image) is reached 
or not.  When the perpendicular images, however, are adjusted and used for analysis it becomes 
evident that sample 23 (Figure 5.5(b)) was indeed reached, as indicated with the circles, hence 
signalling a failure. 
(a) (b) 
(c) (d) 
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          (a)    (b)           (c) 
Figure 5.5: Images after 96 hours adjusted to reveal partial inhibition with bacteria 
reaching all samples a) 17, b) 23, and c) 25 
 
The resultant ZOI areas are graphically presented in Figure 5.6 (X’s indicate the time period at 
which bacteria reached the surface) and Figure 5.7.  The control sample was completely 
overgrown after 24 hours, eliminating the need to investigate for any possible bactericidal effects 
of potentially releasing Titanium-oxide ions.     
 
 
Figure 5.6: ZOI areas against S.aureus Xen 36 over a period of 96 hours 
 
X 
X 
X 
X 
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Figure 5.7: Mean and standard deviation of ZOI areas against S.aureus Xen 36 over a 
period of 96 hours 
 
In contrast to the results obtained above, but as expected, the Xen 31 strain was not inhibited by 
gentamicin concentrations released from the commercial Palacos R+G.  The samples were all 
reached within 24 hours.  This is presented in Figure 5.8, where although some inhibition is 
visible, the samples were reached and therefore signals failure.  Consequently there was no sense 
in measuring any ZOI.  This observation also advocates the importance of appropriate selection 
and use of drugs according to the offending pathogen for both treatment and prophylaxis in 
medical device associated infections.   
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            (a)                            (b)     (c) 
Figure 5.8: Resistant S.aureus Xen 31 reaching each of samples (a) 1, (b) 9, and (c) 16, 
within 24 hours 
 
In summary, the time duration of colonisation prevention for each sample are shown in Table 5.4.  
The susceptible Xen 36, the pathogen of interest, was prevented from colonising for a minimum 
of 72 hours (sample 25), which is well above the reported 6 – 8 hour critical post implantation 
period [175]. 
 
Table 5.4: Colonisation prevention duration for samples 
Sample S.aureus Strain Duration [Hours] 
17 Xen 36 96 
23 Xen 36 96 
25 Xen 36 72 
1 Xen 31 <24 
9 Xen 31 <24 
16 Xen 31 <24 
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5.4 Concluding Remarks 
This pilot study investigated the concept of utilising LaserCUSING
®
 as enabler technology to 
incorporate features in cementless femoral stems from which antimicrobial drugs can be eluted to 
prevent bacterial colonisation. Gentamicin susceptible S.aureus Xen 36 was successfully 
prevented from reaching the biomaterial, whereas the MRSA strain (S.aureus Xen 31) reached all 
the samples within the first 24 hours.  This also correlates with results published in literature 
when cement discs alone were tested [108]. 
 
Various works have reported on the modification and treatment of implant surfaces for drug 
delivery [42].  The novelty of the current concept lies in the objective that it is not only meant to 
be a once-off drug delivery strategy, but that such implants can be reinforced with a liquid drug 
solution via minimally invasive techniques.  Therefore, this study also investigated the porosity of 
a commercial PMMA ALBC, when mixed at different monomer-to-polymer ratios, and the 
possibility of utilising it for controlled drug release.  The main reasons for this were the FDA 
approval status of the cement, the amount of published release studies that could be consulted for 
expected results, and the commercial availability of the product for research purposes.  The 
mixing ratio did not have any significant effect on the porosity (p ≥ 0.8 in all cases) and the 
porosity remained apparent random, individual defects without proper interconnections between 
the pores.  It can be concluded that PMMA ALBC, hand mixed without extra, specialised steps 
such as moulds or inclusion of extra elements, for example chitosan, in the polymer mixture, does 
not readily offer this possibility.  It therefore necessitates the investigation of alternative means to 
enable the administration of multiple drug doses from within the reservoir.   
 
Another issue regarding PMMA ALBCs is the reported concerns on the long lasting release of 
sub inhibitory antibiotic concentration, provoking bacterial resistance [40, 176].  It has been 
reported that as much as more than 90 % of the original loaded amount of antibiotic does not 
release, and reside in the polymer matrix, releasing low concentrations of antimicrobials 
sporadically at unpredictable time periods due to penetration of the dissolution medium through 
cracks and voids into the PMMA matrix [41].  This was also witnessed in the current study, 
where the samples revealed some antimicrobial activity for up to 336 hours against S.aureus Xen 
36, but adequate concentrations for colonisation prevention were only released for a minimum of 
72 hours and a maximum of 96 hours. 
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6. Experimental Method for Reservoir Drug Delivery  
This chapter describes the experimental method for the evaluation of reservoir drug delivery from 
within the samples.  The objective of the experiment is to achieve adequate drug release through 
passive diffusion across nanoporous membranes for multiple injections.  An important aspect is 
the reinforcement possibility, rendering the concept not only a once-off strategy, but one in which 
multiple doses can be administered.   Firstly the experimental setup is described after which the 
quantification method of released vancomycin by RP-HPLC is described. 
 
6.1 In Vitro Release Study 
This part evaluates a commercial nanoporous membrane for localised controlled drug release as 
depicted in Figure 6.1.  The objective is to reach a lower bound of a vancomycin concentration of 
4 x MIC for MRSA (MIC = ±2 µg/ml) quickly.  No restrictions were placed upon an upper 
boundary for local concentrations reached for the reasons discussed in Section 2.2.4.4. 
 
 
 
Figure 6.1: Schematic of vancomycin release across nanoporous membranes from within 
the internal reservoir samples 
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6.1.1 Reservoir Sample Assembly  
To investigate drug delivery by passive diffusion from within the Ti6Al4V reservoir samples, 
PES ultrafiltration flat sheet membranes with a MWCO of 5,000 Da (YMMT 3001, Synder 
Filtration) were identified for incorporation.  Details regarding the selection are documented in a 
different in-house study.   
 
The membranes were cut from the stock into small discs ±8 mm in diameter (Figure 6.2a).  A 
layer of Araldite Rapid epoxy adhesive was carefully spread on the steel ring of stainless steel 
washers having an internal diameter of 6 mm to fit over the channel openings.  Membrane discs 
were then placed onto the stainless steel washers, completely covering the 6 mm internal diameter 
of the washers (Figure 6.2a).  This part is referred to as the sub-assembly (Figure 6.2b).  Another 
layer of adhesive was also carefully applied onto the sample around each channel opening.  A 
sub-assembly was then fixed over a channel opening of the reservoir sample and clamped for a 
minimum 15 minutes.  This was repeated for each channel opening, yielding four membranes in a 
vertical position for passive diffusion (Figure 6.2c).  The bottom channel opening was sealed off 
completely with a commercial antifungal clear silicone (Bostik Mirror), suitable for application in 
damp and warm conditions.  This was to eliminate any possible effects of gravity on the 
simultaneous passive diffusion across membranes placed both vertically and horizontally. 
 
 
      (a)          (b)                               (c) 
Figure 6.2: a) Membrane discs and stainless steel washers separately and b) the sub-
assembly for fixation to the channel openings and c) final reservoir sample assembly 
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6.1.2 Preconditioning of Membranes 
Preconditioning is an important step in the application of ultrafiltration membranes to avoid 
encountering variable fluxes and diffusion behaviours.  A mixture of 60% 1X PBS pH 7.4 and 
40% ethanol (95%) was used for the pre-wetting of the membranes.  The composition of the 1X 
PBS pH 7.4 used is presented in Table 6.1. 
 
Table 6.1: Composition of 1X PBS pH 7.4 
Salt Compound Concentration 
[g/L] 
Concentration 
[mmol/L] 
NaCl 8.0 137 
KCl 0.2 2.7 
Na2HPO4 1.44 10 
KH2PO4 0.24 1.8 
 
 
When PBS alone was used for preconditioning, it was found that air trapped inside the channels 
created a barrier between the introduced liquid and the membrane surface, prohibiting the liquid 
from reaching the inlet side of the membrane for pre-wetting.  The addition of ethanol lowered 
the surface tension of the PBS significantly and allowed the trapped air bubbles to rise through 
the injected liquid and out of the reservoir through the top channel opening.  The PBS-ethanol 
mixture was only utilised for the preconditioning of the membranes.  A syringe needle was used 
to access each channel of the sample individually during the injection of the pre-wetting mixture, 
shown in Figure 6.3.  It was clearly visible when the PBS-ethanol mixture reached and wetted the 
membranes and therefore the membranes were easily monitored for wetting by visual inspection. 
 
 
Figure 6.3: Injection of PBS-ethanol mixture into sample for preconditioning of the 
membranes 
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Since the wetting procedure consumes amounts of the mixture as it is absorbed into the 
membrane, the samples were continuously monitored and filled up during the process to ensure 
complete wetting for preconditioning from the inlet side of each membrane for a minimum of six 
hours, after which the samples were stored fully submerged in a PBS solution.  Each sample was 
also carefully monitored for any signs of leakage during the preconditioning stage before being 
submerged for storage. 
 
6.1.3 Vancomycin Solution Injection 
The vancomycin hydrochloride (Sigma-Aldrich) used in the study was first sent for Liquid 
Chromatography-Mass Spectrometry (LC-MS) with electrospray ionisation (ESI) to the Central 
Analytical Facilities (CAF) at Stellenbosch University to evaluate whether the antibiotic has 
degraded.  The setup and resulting mass spectra are presented in Appendix D.  The molecular ion 
[M+H]
+
 can be seen in Figure D.2 at mass-to-charge (m/z) 1450.4473 which when reduced by the 
one surplus mass unit becomes 1449.4473 Da, is very much in accordance with the theoretical 
value of 1449.25 Da.  The isotopic cluster at 2 charges is presented in Figure D.3 in Appendix D.  
Clear resolution can be witnessed between the isotopes from which the monoisotopic mass is 
calculated as 1447.439 Da, which closely resembles the theoretical value of 1447.4304 Da.  It 
was concluded that the vancomycin was still intact and suitable for use in the reservoir drug 
delivery experiments. 
 
Vancomycin hydrochloride was dissolved in PBS to a stock concentration of 2.5 mg/ml in 
reference to the bolus injections investigated by Young et al. [126].  The Samples were injected 
with the vancomycin solution according to the same procedure followed for membrane 
preconditioning, after which the top channel opening were blocked off with a sheet of parafilm.  
Three injections were made during the duration of the release experiment to test the 
reinforcement possibility.  Each injection volume was set to 400 µl, yielding an injection mass of 
1 mg vancomycin per dose for the release testing. 
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6.1.4 Experimental Setup for Reservoir Drug Release  
Standard 50 ml laboratory glass beakers were used as vessels for the elution tests.  The reservoir 
samples were placed in the centre at the bottom of the beaker.  Each beaker was then filled with 
PBS, which was stored at 37 °C, until the membranes were completely submerged in the buffer as 
presented in Figure 6.4.  Beakers were selected based on the diameter of its base to allow the 
volume of PBS buffer to be large enough for maintaining sink conditions when filled until the 
membranes were submerged.  The selected beakers yielded a buffer volume of 16 ml, which 
adheres to the criteria utilised by Miola et al. [167] where the volume of buffer, Vbuffer [ml], is 
greater than or equal to the surface area [mm
2
] of release divided by 10.  That is, 
 
 
Vbuffer  ≥  
Asurface
10
 (6.1) 
 
and equation 6.1 applied specifically in this study, where the surface area for release is the 
combined area of the four membranes, yields the condition for buffer volume, 
 
Vbuffer   ≥ 
4πr2
10
 
                   ≥  
4π(32)
10
 
                       ≥ 11.31 ml  
 
which is satisfied by a buffer volume of 16 ml.  Sink conditions are used so the released drug 
concentrations in the dissolution medium does not affect the diffusion rate of the drug through the 
respective membrane effectively resulting in one directional movement of the vancomycin 
molecules from inside the reservoir into the buffer. 
 
The beakers were then sealed with plastic wrap to avoid evaporation and placed on a Classic C1 
orbital shaker (New Brunswick Scientific) for continuous agitation at 7 revolutions per minute to 
reduce any boundary layer effects that could affect the release during the experiment (Figure 6.4).  
Samples were kept in the incubator at 37°C for the duration of the elution test intervals and 
briefly removed for aliquot sampling and buffer replacement. 
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Figure 6.4: Experimental setup for reservoir drug release testing  
 
6.1.5 Sampling Procedure  
The sampling schedule is presented in Table 6.2.  Release intervals were determined based on a 
preliminary test during which aliquots were taken and the buffer replaced after intervals of 1, 4, 
and 18 hours, with a cumulative release time of 23 hours.  After 23 hours, a total mass of 635µg 
from the loaded 1 mg vancomycin was released.  Therefore, with the expected release to be 
constrained or near zero order, the injection times were selected accordingly, with the exception 
of the final interval, in an attempt to avoid release of the entire vancomycin reservoir before 
reinforcing the samples with a new vancomycin injection.       
 
Table 6.2: Sampling times for vancomycin release 
Aliquot Number Release Interval 
[Hours] 
Cumulative [Hours] 
N/A 0 0* 
1 1 1 
2 3 4 
3 5 9 
4 8 17 
5 16 33* 
6 24 57* 
7 43 100 
* indicates times at which samples were injected with reinforcing vancomycin solution 
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At each sampling interval the reservoir samples were briefly removed from the beaker, the buffer 
medium inside the beaker stirred by hand for 30s, and a 1 ml aliquot withdrawn.  The aliquots 
were placed in 1.5 ml Eppendorf tubes and stored at -20°C.  The rest of the buffer was discarded 
and the beaker rinsed with PBS.  The samples were placed in the middle of the beakers and again 
16 ml of PBS buffer was added.  At the indicated injection times, the remaining content in the 
reservoir was first withdrawn before injected with fresh vancomycin solution.  The top channels 
were covered with parafilm and the beaker with clear plastic wrap.  The samples were then 
returned to the incubator and placed upon the orbital shaker for the next release interval.    
 
6.2 Vancomycin Quantification with RP-HPLC 
The aliquots taken during the release phase were thawed, filtered and transferred to Chromacol 
autosampler vials (Thermo Scientific) using 17 mm diameter polyvinylidene fluoride (PVDF) 0.2 
µm pore size disposable syringe filters (Thermo Scientific).  The RP-HPLC instrumentation 
utilised was a commercial Finnigan Surveyor Plus unit equipped with its stock Surveyor Plus 
pump and autosampler systems using a sample injection volume of 20 µl.  Detection was done by 
a Surveyor UV/Vis Plus detector set for dual wave length scanning at 254 nm and 280 nm (280 
nm detection specified in the British Pharmacopoeia [132]). 
 
6.2.1 Mobile and Stationary Phases  
For the mobile phase, HPLC grade acetonitrile (AcN) (Merck) with 0.1% trifluoroacetic acid 
(TFA) and, Milli-Q water (EMD Millipore) also with 0.1 % TFA were used.  The stationary 
phase consisted of a Thermo Scientific Hypersil GOLD reversed phase chromatographic column, 
100 mm x 4.6 mm (internal diameter) with C18 chemistry and 5 µm silica particle size.   
   
6.2.2 Gradient Elution Program 
In RP-HPLC, the character of the mobile phase influences the retention time of the solute.  Milli-
Q is a weaker solvent than AcN in RP-HPLC due to the Milli-Q not interacting with the 
hydrophobic surfaces of the stationary phase the solute adsorbs to (Section 2.2.5.2 ).  The addition 
of AcN enables this interaction which breaks the bonds between solute and stationary phase and 
elutes the solute.   
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By adjusting the composition of the mobile phase over time, the retention time of the solute of 
interest can therefore be tailored.  For vancomycin, the retention time was much too low under 
isocratic conditions with a sufficient amount of AcN in the mobile phase, necessitating a gradient 
elution program, presented in Table 6.3.  Preliminary runs revealed an average retention time of 
4.672 ± 0.016 minutes for 14 vancomycin sample injections.  
 
Table 6.3: Mobile phase elution program 
Time [min] Milli-Q (0.1% TFA) [%] AcN (0.1% TFA) [%] Elution Type 
0-1 95 5 isocratic 
1-5 95 - 0 5 – 100 linear gradient 
5-6 0 100 isocratic 
6-11 0-95 100-5 linear gradient 
11-12 95 5 isocratic 
 
 
6.2.3 Calibration Curve 
The known concentration series used for calibration consisted of vancomycin hydrochloride in 
PBS solutions of 0, 5, 12.5, 25, 50, 125, and 250 µg/ml concentrations, injected twice for 
evaluation of linearity.  Integration of the detection peaks as well as the simple linear regression 
was performed automatically by the accompanying control software (ChromQuest 4.2.34 version 
3.1.6).  Linearity of absorbance over this range was also manually evaluated in MSExcel by 
simple linear regression according to the method described by Montgomery and Runger [174]; 
the procedure is presented in Appendix E.  Once the calibration curve was established, the 
unknown vancomycin concentrations in the aliquots could be determined by simply finding the x-
coordinate (of the unknown concentration) for the measured y-coordinate (absorbance).  For this 
once-off proof of concept application, a full validation of the method according to USP 
specifications is outside the scope of the study and not economically feasible.  This will however 
become necessary in the future when the research moves beyond conceptual features and towards 
functional prototypes.  An achievement of a coefficient of determination (R
2
) greater than 0.998 
for all calibration curves was considered sufficient.     
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7. Reservoir Drug Delivery – Results Assessment 
7.1 Reversed Phase High Performance Liquid Chromatography 
A total of 60 injections were made during the sequence in the RP-HPLC analysis.  It consisted of 
7 reference standards for calibration, each injected twice, the 42 samples taken during the release 
period, and 4 internal standards of known concentrations 0, 25, 125, and 250 µg/ml placed at 
arbitrary positions amongst the samples.   
 
7.1.1 Identification of Vancomycin  
The retention time for vancomycin averaged 4.68 ± 0.017 min.  A selection of chromatograms for 
UV detection at 280 nm is presented in Figure 7.1.  The chromatograms result from reference 
standard injections of 5, 50, and 250 µg/ml.  Identified vancomycin peaks, the retention time and 
peak area are indicated for each of the chromatograms.  At the indicated retention time for each, 
the increase in absorbance is clearly visible as the vancomycin concentration increases.   
 
The peaks other than that of vancomycin can be any of a number of compounds either resulting 
from compounds maintained inside the column even after wash, compounds in the mobile phase 
and PBS buffer, compounds or ions released from the materials used for the reservoir samples, or 
degradation products from the vancomycin.  These peaks are not of interest towards the 
investigation of vancomycin release from the reservoir concept.  It is clear from Figure 7.1 that 
the noise imposed by these peaks becomes negligent at very high concentrations of vancomycin 
confirming that the specific compound at the retention time is in fact the vancomycin.   
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Figure 7.1: Chromatograms for reference values of a) 5 b) 50 and c) 250 µg/ml with UV 
detection at 280 nm wavelength 
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7.1.2 Calibration Curves for 254 nm and 280 nm Detection 
Two injections for reference standards of 0, 5, 12.5, 25, 50, 125, and 250 µg/ml concentrations 
were made for evaluating the calibration curve.  Utilising simple linear regression, all four 
calibration curves (two injection series scanned at two wavelengths)  revealed linearity with R
2
 
values greater than 0.998.  The curves from the first injection did however reveal slightly greater 
R
2
 values and are presented in this section with the other curves in Appendix E.   
 
The two replicates of calibration series injections revealed very little, but typical variation in 
detection with the relative ratio of second injection to first injection fluctuating very closely 
around one.  Response peak areas of absorbance for the two replicates are presented for 254 nm 
in Table 7.1 and 280 nm in Table 7.2.  It is important to note that the second injection of the first 
aliquot, a blank consisting only of PBS, did not withdraw enough from the vile, and therefore did 
not inject any sample, consequently yielding no detection.   
 
Table 7.1: Reference standards and peak response areas for calibration dilution series at 
254 nm UV detection 
Standard 
Number 
Concentration 
[µg/ml] 
Response Peak Area @ 
254 nm 
Ratio I2/I1 
  Injection1 (I1)   Injection2 (I2)  
1 0 178681 ---
a
 --- 
2 5 244618 243882 0.9970 
3 12.5 395502 391505 0.9899 
4 25 652763 652588 0.9997 
5 50 1119492 1120264 1.0007 
6 125 2497347 2509887 1.0050 
7 250 4611234 4586338 0.9946 
a
No response peak detected for the second injection due to a lack of sample quantity in the vial 
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Table 7.2: Reference standards and peak response areas for calibration dilution series at 
280 nm UV detection 
Standard 
Number 
Concentration 
[µg/ml] 
Response Peak Area @ 
280 nm 
Ratio I2/I1 
  Injection1 (I1)   Injection2 (I2)  
1 0 36356 ---
a
 --- 
2 5 93726 89054 0.9502 
3 12.5 235294 259945 1.1048 
4 25 484550 487392 1.0059 
5 50 948790 958742 1.0105 
6 125 2360237 2379099 1.0080 
7 250 4692199 4660898 0.9933 
a
No response peak detected for the second injection due to a lack of sample quantity in the vial 
 
 
In accordance with the RP-HPLC software, the response area of the first injection for standard 1 
was also used for injection 2 to determine the calibration curves for the second injections 
(Appendix E).  The resulting calibration curves for the first injections are presented in Figures 7.2 
and 7.3 with the estimated parameters of the linear regression models in Table 7.3 for UV 
detection at wavelengths 254 and 280 nm respectively. 
 
 
Figure 7.2: Calibration curve for UV detection at 254 nm 
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Figure 7.3: Calibration curve for UV detection at 280 nm 
 
 
Table 7.3: Regression parameters for calibration curves 
Regression Parameters Detection Wavelength [nm] 
254 280 
Slope Estimator 17838.27 14220.68 
Intercept Estimator 194321.08 18720.02 
Coefficient of Determination [R
2
] 0.99933 0.99995 
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The released mass of vancomycin is obtained by multiplying the detected concentration by the 
buffer volume.  A two-tailed Student t-test (assumed equal variances) for independent samples 
was executed in MSExcel to evaluate for any statistical significant difference between average 
concentrations and released masses obtained from the two wavelengths both for intervallic and 
cumulative arrangements.  The sample size was seven and the significance level, α = 0.05.  The 
null hypothesis states that all concentrations are from the same population irrespective of the 
wavelength.   
 
H0: μ1 = μ2 
H1: μ1 ≠ μ2 
 
The results are presented in Table 7.4.  Since the MSExcel procedure was already manually 
verified, it was not repeated here.  There is absolutely no statistical significance in whether 
concentrations calculated from either of the wavelengths are utilised.  However, the R
2
 value for 
the calibration curve at 280 nm wavelength detection is more accurate.  It is also the wavelength 
specified in the prior mentioned pharmacopoeias.  Hence the results from 280 nm wavelength are 
used.   
 
Utilising this calibration curve (Figure 7.3) the concentrations detected for the known internal 
standards containing vancomycin were 24.29, 127.86, and 254.91 µg/ml respectively, yielding 
accuracies of 97.18%, 102.29%, and 101.97% which are all within a 5% deviation.  An 
anomalous detection of 8.08 µg/ml was found for the 0 µg/ml standard.  The exact causes of 
which are unknown but possible influences could be vancomycin transfer within the column or 
other areas such as the syringe in the autosampler, or vancomycin contamination during 
preparation of the standard.  Based on the high accuracy of detection regarding the other three 
standards, and that the preparation of the standards occurred at a physically different location than 
preparation of the vials containing aliquots taken during the release period, the method is still 
considered applicable. 
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Table 7.4: t-Test results revealing no significant difference in concentrations obtained from detection at 254 nm or 280 nm  
Mode Time [Hours] Average Concentration [µg/ml] @ P – Value Average Mass Released [µg]  @ P-Value 
  254 nm Detection 280 nm Detection  254 nm Detection 280 nm Detection  
Intervallic 1 3.03 3.96 
0.9768 
48.46 63.42 
0.9766 
 3 6.55 7.45 104.73 119.19 
 5 8.21 9.19 131.31 146.97 
 8 9.80 10.59 156.74 169.45 
 16 10.90 11.71 174.32 187.35 
 24 42.04 41.52 672.56 664.30 
 43 69.82 68.66 1117.07 1098.63 
        
Cumulative 1 3.03 3.96 
0.9195 
48.46 63.42 
0.9195 
 4 9.57 11.41 153.19 182.61 
 9 17.78 20.60 284.50 329.58 
 17 27.58 31.19 441.24 499.04 
 33 38.47 42.90 615.56 686.38 
 57 80.51 84.42 1288.13 1350.69 
 100 150.32 153.08 2405.19 2449.31 
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It is also evident from Table 7.4 that the release is closely related to that of the preliminary 
experiments on which the sampling times for the actual experiment were based.  As expected, the 
total amount of injected vancomycin did release in the 43 hour interval.  This indicates both that 
effective sink conditions were maintained and that drug molecules did not re-enter the reservoir 
once they were released.  The average mass released is greater than 1000 µg, which can be 
ascribed to slight variations in injection volumes as a result of imprecise measurements taken 
visually from the syringe volume scale, imprecise calibration of the syringe volume scales, or 
injection technique introduced variations.  It is nevertheless very close to the intended 1000 µg. 
 
7.2 Release Profile and Mechanism 
7.2.1 Identification of Release Profile 
The release for the entire 100 hour period is indicated in Figure 7.4 as cumulative concentration 
that would have been present in the buffer and in Figure 7.5 as the cumulative of the vancomycin 
mass released, based on the intended 400 µl (containing 1000 µg vancomycin) injection volumes.  
The instances of injection times are indicated in both of these figures. 
 
 
Figure 7.4: Cumulative concentration in PBS buffer of vancomycin released over 100 Hours 
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Figure 7.5: Cumulative mass of vancomycin released from reservoir 
 
The release profile can be deduced from the samples takes within the first injection period.  Since 
the reservoirs were emptied before new injections, and sink conditions were maintained, it is 
argued that the release profile obtained within the first would also be present in each of the release 
periods following a fresh injection.  The profile, based on the first injection, is shown in Figure 
7.6. 
 
 
Figure 7.6: Cumulative release profile for vancomycin mass released during first injection 
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7.2.2 Establishment of Release Mechanism 
Visually from Figure 7.6, the release mechanism appears to be neither Fickian nor zero-order 
release, but a type of constraint release as effected by the nanoporous nature of the PES membrane.   
The Korsmeyer-and-Peppas model (Equation 2.1) discussed in Section 2.2.4.5 is applied to 
determine the release mechanism.  Since the Korsmeyer and Peppas model requires for the release 
fraction to not exceed 60%, only the data for the average release that falls below 60% of the total 
injected amount is considered.  It is presented in Figure 7.7 as the average and standard deviation 
for the six samples’ cumulative release percentage below 60%. 
 
 
Figure 7.7: Average and standard deviation of cumulative release percentage for all samples 
below 60% of total introduced amount 
 
In order to determine the values of K and n for the Korsmeyer-and-Peppas model, the model is first 
linearised from Equation 7.1 by employing natural logarithms as follows, 
 
 
 
Mt
M∞
= Ktn (7.1) 
 
ln (
Mt
M∞
) = ln(Ktn)  
 
       l n (
Mt
M∞
)  = lnK+ln(tn) (7.2) 
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The cumulative released percentage can be plotted in the linearised form and evaluated with 
simple linear regression.  This linearised form of data is represented as a plot of the natural 
logarithms of the cumulative release percentage to the natural logarithm of time.  The resulting 
graph of the linearised data, along with its linear regression line is presented in Figure 7.8. 
 
 
Figure 7.8: Observed cumulative release percentage linearised according to Korsmeyer-and-
Peppas release model 
 
It is evident that observed data exhibits a very high degree of linearity, indicating that the 
Korsmeyer-and-Peppas model would indeed be a good fit.  The value of K can be determined by 
utilising Equation 7.2, that is, 
 
lnK = 1.8649 
    K =  e1.8649 
        = 6.4551 
 
The value of n is then determined by utilising Equation 7.1, together with the observed data and 
employing a minimise function with MSExcel Solver, based on the sum of square errors method. 
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Another two-tailed Student t-test (assumed equal variances) for independent samples was executed 
in MSExcel to evaluate for any statistical significant difference between observed and modelled 
cumulative release percentage values below 60%.  The sample size was four and the significance 
level, α = 0.05.  The null hypothesis states that all cumulative release percentages are from the 
same population. 
 
Therefore, 
 
H0: μ1 = μ2 
H1: μ1 ≠ μ2 
 
The resulting approximations, minimised sum of square errors and P-value for the t-Test on the 
means are presented in Table 7.5.  The value obtained for n is 0.7264, identifying the release 
mechanism as non-Fickian anomalous (constraint) release.  This indicates that the drug is not 
released through diffusion alone, but interactions between the drug and the polymer structure also 
affects and controls the rate of release, a desired release profile for quickly reaching and then 
sustaining high concentrations of the drug in the local vicinity of the implant. 
 
Table 7.5: Fitting of Korsmeyer-and-Peppas model to first 60% of cumulative drug release 
Time 
[Hours] 
Observed Cumulative 
Release [%] 
Estimated Cumulative 
Release [%] 
Square 
Error 
Sum of Square 
Errors 
P-Value 
1 6.342 6.455 0.013 
2.012 0.9686 
4 18.261 17.670 0.350 
9 32.958 31.847 1.235 
17 49.904 50.548 0.415 
 
 
The release can therefore be considered as a non-specific constraint release.  Calculated values for 
the parameters of the Korsmeyer-and-Peppas model are substituted into Equation 7.1 and plotted 
against the observed data in Figure 7.9 for the cumulative release percentage below 60% of the 
injected amount over time.  The high P-value in Table 7.5 indicates that there is absolutely no 
reason to reject the hypothesis that the two curves represents the same population. 
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Figure 7.9: Observed data and Korsmeyer-and-Peppas Model data for cumulative release 
percentage below 60% of injected amount 
 
Since the concentration of vancomycin in the buffer is dependent on buffer volume when released 
mass is kept constant, determining the exact time it took to reach 8 µg/ml bares not that much 
information.  Instead the fitted Korsmeyer-and-Peppas model can be modified in terms of the 
method utilised in this study to represent the time to 4 times MIC as an equation dependent on 
concentration and buffer volume.  Consider the fitted model, 
 
 Mt
M∞
 = 6.4551t0.7264 (7.3) 
 
in which the mass released at time t, is determined by measuring the concentration in the buffer at 
time t, Ct, and multiplying it with the buffer volume, Vbuffer, that is, 
 
 Mt = Ct × Vbuffer (7.4) 
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Substituting Equation 7.4 into Equation 7.3,  
 
 (Ct × Vbuffer)
M∞
 = 6.4551t0.7264 
 
 
and rearranging to let time, t, be the subject the equation becomes, 
 
 
 t = [
1
0.64551
 (
Ct × Vbuffer
M∞
)]
1
0.7264 (7.5) 
 
which can be utilised to find times to reach desired concentrations in different buffer sizes given 
that the cumulative released mass percentage is below 60% and the buffer is maintained at sink 
conditions.  Applied to this study, Equation 7.5 yields a time of 2.57 hours for reaching a 
concentration of 8 µg/ml. 
 
7.3 Concluding Remarks 
The reservoir release for multiple injections of a vancomycin hydrochloride – PBS solution by 
means of passive diffusion across a nanoporous membrane into a PBS buffer under sink conditions 
has been investigated.  Three injections were made at specific time intervals during a total 
experimental release period of 100 hours.  For a single injection, and with reference to the buffer 
volume in this study, concentration levels above the MIC for MRSA were reached after 1 hour, 
with a 4 times MIC (8 µg/ml) concentration reached within 3 hours of release.   
 
Three injections were made to evaluate the use of the concept as a non once-off strategy, but as 
one during which multiple doses could be administered.  Similar release rates were observed 
throughout these injections, with the last injection interval of 43 hours releasing the entire reservoir 
as was expected from preliminary tests.  The release mechanism was determined to be non-
Fickian, possibly being controlled by both diffusion and factors relating to changes in the structure 
of the polymer matrix such as relaxation, ultimately resulting in a constraint release.  An appealing 
aspect of this profile is that the desired concentration can be achieved quicker than with single file 
diffusion whilst avoiding a burst release, and the release rate then maintained at a near zero-order 
level.  Furthermore, since the idea behind single file diffusion is that molecules are released 
singularly from pores or vacancies inside the polymer matrix, it stands to reason that one of very 
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few ways to increase the release amount from such a system would be to increase the surface area 
of the polymer used as release membrane.  This is not necessarily feasible for application in 
implants where space is limited and the detrimental effects on mechanical properties due to 
material removal should be minimised. 
 
In conclusion, the concept has proven to allow for adequate vancomycin release from the reservoir 
for three injections, therefore moving the concept beyond the barrier of once-off release strategies.  
A new approach regarding LaserCUSING
®
 as the enabler technology opens possibilities for drug 
delivery from within medical implants as part of an infection treatment regimen. 
 
The Korsmeyer-and-Peppas model was used to evaluate the release mechanism and also resulted in 
a very close approximation for the first 60% of cumulative mass released from the reservoir.  Once 
the model has been fitted to a given situation empirically, it could be modified to indicate the time 
needed for achieving a desired concentration, providing that the buffer volume is known and is 
maintained at sink conditions. 
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8. Conclusion and Future Research 
8.1 Conclusion 
Bacterial colonisation onto hip replacement stems remains a devastating complication with 
escalating expenses and serious morbidity for the patient.  The current two-stage treatment 
procedure for biofilm infection leaves the patient with an interim period of a minimal load 
bearing antibiotic loaded spacer, an aggressive regimen of antibiotic treatment, and very little 
mobility.  Furthermore, eradication of infection cannot be guaranteed and the interim cycle may 
need to be repeated.  Therefore the overall objective of the study was to contribute to the field of 
infection prevention and treatment strategies for cementless femoral stems.  This objective has 
been achieved by working on each of the supporting objectives as set out in Section 1.3. 
 
 Reports on the performance of commercial ALBC was translated from literature to 
develop conceptual drug delivery features which were successfully used to both convey 
the idea behind and evaluate the concept 
 AM in the proprietary form of LaserCUSING® was applied appropriately for the 
fabrication of samples containing these drug delivery features 
 It has been shown that when an antibiotic is applied appropriately according to the main 
pathogen of concern that colonisation of the titanium alloy can be prevented in vitro 
using an FDA approved commercial ALBC within these samples, thereby creating a way 
to incorporate these materials for prophylaxis in cementless stems too 
 The drug delivery concept allowed the in vitro sustained release of multiple dosages of a 
high level antibiotic typically used in the treatment of MRSA infections.  
 
The main research question can thus be answered that it is possible to prevent colonisation onto, 
and enable controlled drug release through samples containing drug delivery features 
manufactured by SLM.  This however has been an initial investigation into this field for 
application of SLM towards infection prevention and treatment strategies but provides a basis for 
more detailed and specialised studies towards developing a fully functional prototype.  Such a 
functional cementless femoral stem is envisioned to reduce the current two-stage procedure used 
for treating serious implant infections to a single stage procedure, removing the need for interim 
cement spacers. This will lead to a significant reduction in operating theatre occupation times and 
a reduction in costs for both the patients and medical aid companies 
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8.2 Future Research 
An important aspect of the concept is that it is not restricted to hip replacement stems, but can be 
incorporated in any bulk metallic implants for example shoulder, knee or pelvic implants.  It is 
also not restricted to the administration of antimicrobial drugs, and can also be utilised to release 
for example, anti-inflammatories or osteoconductive compounds. 
 
The evaluation of drug formulations can ensue to find those which would exhibit adequate 
stability over a long term period.  Each drug molecule has unique properties with regard to 
degradation, and these need to be considered in future research when developing a formulation 
for a specific application. 
 
As technology advances and the tempo at which novel research is published, it would be 
necessary to maintain an outlook at alternatives for release membranes should this option be 
considered in additional studies.  A very suitable system could be one consisting of the same 
material than the implant itself, such as titanium alloy, which would not be biodegradable to the 
extent that would cause rupturing and bulk release of the reservoir drug.   
 
Medical devices are monitored and need to adhere to stringent regulatory issues.  Therefore future 
research should also evaluate the effects on the mechanical properties by removing material from 
the bulk structure for the internal channels.  Load bearing medical implants such as hip stems 
have to be proven to conform to international standards for cementless femoral stems, especially 
with regards to fatigue strength.  
 
In terms of osseointegration, an additional research avenue is the investigation of possible porous 
surfaces for bone ingrowth onto as-built LaserCUSING
®
 parts.  The compliance of these surfaces, 
however, has not yet been tested according to international specifications for medical implants. 
Consequently, part of the outlook is the characterisation of the as-build surfaces according to 
ASTM standards (ASTM F2068, F1044, F1147, F1978) for porous coatings of medical implant 
devices.   
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Appendix A: t-Test Statistics 
Each random variable, X1, X2, … , Xn for a sample size of n has the arithmetic sample mean ?̅?, 
 
 
?̅? =  
1
𝑛
 ∑ 𝑥𝑖
𝑛
𝑖=1
 (A.1) 
 
and sample variance, 
 
 
𝑠2 = (∑(𝑥𝑖 − ?̅?)
2 
𝑛
𝑖=1
) (𝑛 − 1)⁄  (A.2) 
 
where the sample standard deviation is the square root of the sample variance.  
 
The two sample variances S1
2
 and S2
2
 are combined to create an estimator of σ2.  This is called the 
pooled estimator, Sp
2
. 
 
 
𝑆𝑝
2 =  
(𝑛1 − 1)𝑆1
2 + (𝑛2 − 1)𝑆2
2
𝑛1  + 𝑛2 − 2
 (A.3) 
 
The Test T-statistic is then calculated by,  
 
 
𝑇 =  
?̅?1 −  ?̅?2 −  (𝜇1 −  𝜇2)
𝑆𝑝√
1
𝑛1
+  
1
𝑛2
 
(A.4) 
 
which has a t distribution with n1 + n2 – 2 degrees of freedom. 
 
Once the T-statistic has been calculated, the hypothesis test can proceed in two ways, since one 
implies the other.  The calculated T-statistic can be compared to Tcrit where Tcrit is read from the 
standard t-table, or the P-values can be used.  H0 should be rejected if the calculated T-statistic is 
greater than Tcrit or if the P-value accompanying the calculated T-statistic is smaller than the 
level of significance α (0.05 in this study).  The porosities from the CT-scans are presented below 
in Figure A.1 
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Figure A.1: Summary of porosities of bone cement samples 
 
The following figures reveal both the t-test calculations for each of the three combinations, done 
both with the MSExcel built in function and by manually entering the formulas.  The alternative 
hypothesis stated that the means are unequal.  Therefore, the two-tailed P-values from the 
MSExcel function were used for comparison to the manual calculations.  
 
 
Figure A.2: MSExcel and manually calculated t-Test results for ratios 1:2 and 1:1.5 
 
Porosities for bone cement samples
Ratio
Sample 1 to 2 1 to 1.5 1 to 1
1 1.37 5.37 3.73
2 2.29 2.35 2.74
3 4.18 1.31 2
Mean 2.61 3.01 2.82
StdDev 1.43 2.11 0.87
Var 2.05 4.45 0.75
t-TEST EXCEL BLACK BOX t-TEST MANUAL CALCULATIONS
1:2 and 1:1.5 (alpha 0.05) 1:2 and 1:1.5 (alpha 0.05)
t-Test: Two-Sample Assuming Equal Variances t-Test: Two-Sample Assuming Equal Variances
Variable 1 Variable 2 1 to 2 1 to 1.5
Mean 2.613333333 3.01 sample mean 2.613333333 3.01
Variance 2.052433333 4.4476 sample variance 2.052433333 4.4476
Observations 3 3 Estimator Sp^2 3.250016667
Pooled Variance 3.250016667 Estimator Sp 1.80278026
Hypothesized Mean Difference 0 t-statistic -0.269481243
df 4 T(α/2),n1+n2-2 (from t-table) 2.776
t Stat -0.269481243 (-)T(α/2),n1+n2-2 -2.776
P(T<=t) one-tail 0.400444833 P-Value (from t-table) 0.8
t Critical one-tail 2.131846782
P(T<=t) two-tail 0.800889666
t Critical two-tail 2.776445105
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Figure A.3: MSExcel and manually calculated t-Test results for ratios 1:2 and 1:1 
 
 
 
Figure A.4: MSExcel and manually calculated t-Test results for ratios 1:1.5 and 1:1 
 
Based on the above comparisons, it was deemed valid to only utilise the MSExcel function for the 
remainder of the t-Tests carried out during the study.  Screen shots of these are shown below. 
 
 
 
t-TEST EXCEL BLACK BOX t-TEST MANUAL CALCULATIONS
1:2 and 1:1 (alpha 0.05) 1:2 and 1:1 (alpha 0.05)
t-Test: Two-Sample Assuming Equal Variances t-Test: Two-Sample Assuming Equal Variances
Variable 1 Variable 2 1 to 2 1 to 1
Mean 2.613333333 2.823333 sample mean 2.613333333 2.823333
Variance 2.052433333 0.753433 sample variance 2.052433333 0.753433
Observations 3 3 Estimator Sp^2 1.402933333
Pooled Variance 1.402933333 Estimator Sp 1.184454868
Hypothesized Mean Difference 0 t-statistic -0.217143287
df 4 T(α/2),n1+n2-2 (from t-table) 2.776
t Stat -0.217143287 (-)T(α/2),n1+n2-2 -2.776
P(T<=t) one-tail 0.419361379 P-Value (from t-table) > 0.8
t Critical one-tail 2.131846782
P(T<=t) two-tail 0.838722757
t Critical two-tail 2.776445105
t-TEST EXCEL BLACK BOX t-TEST MANUAL CALCULATIONS
1:1.5 and 1:1 (alpha 0.05) 1:1.5 and 1:1 (alpha 0.05)
t-Test: Two-Sample Assuming Equal Variances t-Test: Two-Sample Assuming Equal Variances
Variable 1 Variable 2 1 to 1.5 1 to 1
Mean 3.01 2.823333 sample mean 3.01 2.823333
Variance 4.4476 0.753433 sample variance 4.4476 0.753433
Observations 3 3 Estimator Sp^2 2.600516667
Pooled Variance 2.600516667 Estimator Sp 1.612611753
Hypothesized Mean Difference 0 t-statistic 0.141769426
df 4 T(α/2),n1+n2-2 (from t-table) 2.776
t Stat 0.141769426 (-)T(α/2),n1+n2-2 -2.776
P(T<=t) one-tail 0.447057904 P-Value (from t-table) >> 0.8
t Critical one-tail 2.131846782
P(T<=t) two-tail 0.894115807
t Critical two-tail 2.776445105
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Figure A.5: MSExcel t-Test results comparing interval concentrations at different wavelengths 
 
 
Figure A.6: MSExcel t-Test for comparing cumulative concentrations at different wavelengths 
 
 
Figure A.7: MSExcel t-Test results comparing interval mass release at different wavelengths 
Obs Time Concentration [µg/ml] @ t-Test: Two-Sample Assuming Equal Variances
Interval Wavelength [nm]
254 280 Variable 1 Variable 2
1 1 3.03 3.96 Mean 21.47857143 21.8685714
2 3 6.55 7.45 Variance 624.5380476 582.562914
3 5 8.21 9.19 Observations 7 7
4 8 9.8 10.59 Pooled Variance 603.550481
5 16 10.9 11.71 Hypothesized Mean Difference 0
6 24 42.04 41.52 df 12
7 43 69.82 68.66 t Stat -0.029699
P(T<=t) one-tail 0.488397667
t Critical one-tail 1.782287548
P(T<=t) two-tail 0.976795334
t Critical two-tail 2.178812827
Obs Time Concentration [µg/ml] @ t-Test: Two-Sample Assuming Equal Variances
Cumul Wavelength [nm]
254 280 Variable 1 Variable 2
1 1 3.03 3.96 Mean 46.75142857 49.6514286
2 4 9.57 11.41 Variance 2739.263581 2781.13801
3 9 17.78 20.6 Observations 7 7
4 17 27.58 31.19 Pooled Variance 2760.200798
5 33 38.47 42.9 Hypothesized Mean Difference 0
6 57 80.51 84.42 df 12
7 100 150.32 153.08 t Stat -0.103267029
P(T<=t) one-tail 0.459728391
t Critical one-tail 1.782287548
P(T<=t) two-tail 0.919456782
t Critical two-tail 2.178812827
Obs Time Mass [µg] @ t-Test: Two-Sample Assuming Equal Variances
Interval Wavelength [nm]
254 280 Variable 1 Variable 2
1 1 48.46 63.42 Mean 343.5985714 349.90143
2 3 104.73 119.19 Variance 159879.4068 149151.19
3 5 131.31 146.97 Observations 7 7
4 8 156.74 169.45 Pooled Variance 154515.2999
5 16 174.32 187.35 Hypothesized Mean Difference 0
6 24 672.56 664.3 df 12
7 43 1117.07 1098.63 t Stat -0.029997547
P(T<=t) one-tail 0.488281073
t Critical one-tail 1.782287548
P(T<=t) two-tail 0.976562147
t Critical two-tail 2.178812827
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Figure A.8: MSExcel t-Test results comparing cumulative mass release at different wavelengths 
 
 
 
Figure A.9: MSExcel t-Test results for evaluating Korsmeyer-and-Peppas estimates to observed 
values 
 
 
 
Obs Time Mass [µg] @ t-Test: Two-Sample Assuming Equal Variances
Cumul Wavelength [nm]
254 280 Variable 1 Variable 2
1 1 48.46 63.42 Mean 748.0385714 794.43286
2 4 153.19 182.61 Variance 701274.7586 711961.32
3 9 284.5 329.58 Observations 7 7
4 17 441.24 499.04 Pooled Variance 706618.0386
5 33 615.56 686.38 Hypothesized Mean Difference 0
6 57 1288.13 1350.69 df 12
7 100 2405.19 2449.31 t Stat -0.103253826
P(T<=t) one-tail 0.45973352
t Critical one-tail 1.782287548
P(T<=t) two-tail 0.91946704
t Critical two-tail 2.178812827
t-Test: Two-Sample Assuming Equal Variances
Time Observed K-P Estimate Variable 1 Variable 2
1 6.342 6.455 Mean 26.62996752 26.86637832
4 18.261 17.67 Variance 362.1923069 354.368227
9 32.958 31.847 Observations 4 4
17 49.904 50.548 Pooled Variance 358.280267
Hypothesized Mean Difference 0
df 6
t Stat -0.01766326
P(T<=t) one-tail 0.493240102
t Critical one-tail 1.943180274
P(T<=t) two-tail 0.986480203
t Critical two-tail 2.446911846
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Appendix B: ZOI Measurement Data 
ZOI data after 24 Hours for Sample 17 
 
 
Figure B.1: 24 Hour photographs for Sample 17  
 
Table B.1: 24 Hour ZOI measurements for Sample 17  
 Image 3737 Image 3747 
Measurement 
Number 
ZOI without Sample 
Surface [mm
2
] 
ZOI without Sample 
Surface [mm
2
] 
1 701.60 683.29 
2 700.90 686.03 
3 704.84 685.14 
4 699.40 686.40 
5 699.85 682.99 
6 701.08 685.73 
7 697.14 689.36 
8 701.15 686.17 
9 700.03 689.10 
10 701.88 680.95 
Average 700.79 685.517 
Sample Average ± 
Standard Deviation 
693.15 ± 8.15 
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ZOI data after 24 Hours for Sample 23 
 
 
Figure B.2: 24 Hour photographs for Sample 23  
 
Table B.2: 24 Hour ZOI measurements for Sample 23  
 Image 3730 Image 3743 
Measurement 
Number 
ZOI without Sample 
Surface [mm
2
] 
ZOI without Sample 
Surface [mm
2
] 
1 789.73 782.48 
2 783.58 787.60 
3 791.17 786.14 
4 775.72 787.62 
5 782.61 784.30 
6 786.58 778.59 
7 782.42 780.03 
8 784.07 781.66 
9 783.10 785.82 
10 783.77 783.73 
Average 784.27 783.80 
Sample Average ± 
Standard Deviation 
784.04 ± 3.64 
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ZOI data after 24 Hours for Sample 25 
 
 
Figure B.3: 24 Hour photographs for Sample 25  
 
Table B.3: 24 Hour ZOI measurements for Sample 23  
 Image 3734 Image 3746 
Measurement 
Number 
ZOI without Sample 
Surface [mm
2
] 
ZOI without Sample 
Surface [mm
2
] 
1 694.57 699.75 
2 692.68 697.81 
3 696.65 696.03 
4 699.36 698.01 
5 698.81 697.31 
6 694.94 694.67 
7 691.75 694.82 
8 687.60 699.59 
9 691.65 697.50 
10 690.38 695.75 
Average 693.84 697.12 
Sample Average ± 
Standard Deviation 
695.48 ± 3.32 
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ZOI data after 48 Hours for Sample 17 
 
 
Figure B.4: 48 Hour photographs for Sample 17 
 
Table B.4: 48 Hour ZOI measurements for Sample 17 
 Image 3766 Image 3775 
Measurement 
Number 
ZOI without Sample 
Surface [mm
2
] 
ZOI without Sample 
Surface [mm
2
] 
1 271.36 266.29 
2 269.54 263.84 
3 253.69 259.57 
4 256.41 254.52 
5 265.94 258.07 
6 258.84 256.16 
7 256.68 254.65 
8 253.61 254.01 
9 255.33 253.38 
10 256.61 255.42 
Average 259.80 257.59 
Sample Average ± 
Standard Deviation 
258.70 ± 5.59 
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ZOI data after 48 Hours for Sample 23 
 
 
Figure B.5: 48 Hour photographs for Sample 23 
 
Table B.5: 48 Hour ZOI measurements for Sample 23 
 Image 3765 Image 3772 
Measurement 
Number 
ZOI without Sample 
Surface [mm
2
] 
ZOI without Sample 
Surface [mm
2
] 
1 250.94 254.84 
2 252.90 253.62 
3 252.70 255.78 
4 254.28 256.64 
5 256.31 254.64 
6 254.78 255.54 
7 252.18 253.51 
8 252.42 252.53 
9 254.32 255.64 
10 253.25 254.65 
Average 253.41 254.75 
Sample Average ± 
Standard Deviation 
254.07 ± 1.52 
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ZOI data after 48 Hours for Sample 25 
 
 
Figure B.6: 48 Hour photographs for Sample 25 
 
Table B.6: 48 Hour ZOI measurements for Sample 25 
 Image 3766 Image 3775 
Measurement 
Number 
ZOI without Sample 
Surface [mm
2
] 
ZOI without Sample 
Surface [mm
2
] 
1 245.41 235.38 
2 246.15 238.34 
3 243.48 237.14 
4 246.05 238.62 
5 238.04 235.01 
6 239.51 237.11 
7 241.65 240.11 
8 242.27 238.39 
9 243.26 237.40 
10 240.95 235.82 
Average 242.68 237.33 
Sample Average ± 
Standard Deviation 
240.00 ± 3.51 
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ZOI data after 72 Hours for Sample 17 
 
 
Figure B.7: 72 Hour photographs for Sample 17 
 
Table B.7: 72 Hour ZOI measurements for Sample 17 
 Image 3899 Image 3828 
Measurement 
Number 
ZOI without Sample 
Surface [mm
2
] 
ZOI without Sample 
Surface [mm
2
] 
1 243.87 243.16 
2 241.57 239.47 
3 237.96 238.05 
4 247.61 238.55 
5 241.84 239.74 
6 242.59 239.88 
7 240.32 237.84 
8 239.69 235.84 
9 234.36 238.02 
10 238.94 237.36 
Average 240.88 238.79 
Sample Average ± 
Standard Deviation 
239.83 ± 3.00 
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ZOI data after 72 Hours for Sample 23 
 
 
Figure B.8: 72 Hour photographs for Sample 23 
 
Table B.8: 72 Hour ZOI measurements for Sample 23 
 Image 3831 Image 3832 
Measurement 
Number 
ZOI without Sample 
Surface [mm
2
] 
ZOI without Sample 
Surface [mm
2
] 
1 330.52 329.31 
2 329.26 327.97 
3 330.69 331.78 
4 332.28 330.52 
5 331.81 329.36 
6 331.32 331.12 
7 330.38 330.41 
8 329.89 331.34 
9 330.53 331.01 
10 330.13 330.03 
Average 330.68 330.28 
Sample Average ± 
Standard Deviation 
330.48 ± 1.03 
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ZOI data after 72 Hours for Sample 25 
 
 
Figure B.9: 72 Hour photographs for Sample 25 
 
Table B.9: 72 Hour ZOI measurements for Sample 25 
 Image 3833 Image 3835 
Measurement 
Number 
ZOI without Sample 
Surface [mm
2
] 
ZOI without Sample 
Surface [mm
2
] 
1 169.88 169.58 
2 172.07 170.13 
3 174.53 169.02 
4 172.61 170.78 
5 172.14 171.40 
6 167.48 170.02 
7 165.48 167.79 
8 167.37 168.09 
9 167.92 167.83 
10 166.97 168.99 
Average 169.65 169.36 
Sample Average ± 
Standard Deviation 
169.50 ± 2.25 REACHED 
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ZOI data after 96 Hours for Sample 17 
 
 
Figure B.10: 96 Hour photographs for Sample 17 
 
Table B.10: 96 Hour ZOI measurements for Sample 17 
 Image 3917 Image 3909 
Measurement 
Number 
ZOI without Sample 
Surface [mm
2
] 
ZOI without Sample 
Surface [mm
2
] 
1 164.12 165.85 
2 162.99 165.21 
3 162.27 164.25 
4 162.94 156.56 
5 163.28 157.91 
6 162.78 158.27 
7 162.22 158.20 
8 162.80 159.01 
9 160.73 158.73 
10 159.32 158.46 
Average 162.34 160.24 
Sample Average ± 
Standard Deviation 
161.30 ± 2.76 REACHED 
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ZOI data after 96 Hours for Sample 23 
 
 
Figure B.10: 96 Hour photographs for Sample 17 
 
Table B.10: 96 Hour ZOI measurements for Sample 17 
 Image 3911 Image 3916 
Measurement 
Number 
ZOI without Sample 
Surface [mm
2
] 
ZOI without Sample 
Surface [mm
2
] 
1 202.27 200.68 
2 200.88 201.62 
3 200.78 202.19 
4 202.82 201.82 
5 202.46 201.45 
6 202.82 200.84 
7 201.42 200.35 
8 200.56 201.30 
9 201.25 200.52 
10 200.68 201.56 
Average 201.59 201.23 
Sample Average ± 
Standard Deviation 
201.41 ± 0.77 REACHED 
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Appendix C: Antibiotics in Clinical Use 
Table C.1: Summary of antibiotic properties (from reference [85]) 
Class/Drug Molecular 
Weight 
[g/mol] 
Water 
Solubility 
[mg/ml] 
pH induced 
in 
Surrounding 
Solubility in 
Organic 
Solvents 
Melting 
Temperature 
[°C] 
Antibacterial 
Spectrum 
Aminoglycosides      Broad spectrum, 
many Gram-positive 
and Gram-negative 
bacteria 
Amikacin 585.6 185 (highly 
soluble) 
Base Insoluble 220-230 
(decomposes) 
Gentamicin 477.6 100 (highly 
soluble) 
Base DMF, MeOH, 
Ether, CHCl3, 
Acetone. Low 
solubility: 
DMSO   
102-108 
(Hydrochloride 
194-209) 
Tobramycin 467.5 538 (highly 
soluble) 
Base Low: EtOH 168 
Cefalosporins      Gram-positive, with 
increased activity 
against Gram-
negative bacteria 
Cefazolin 454.5 0.487 
(slightly 
soluble) 
Weak acid DMF, 
Pyridine, 
Acetone. 
Low: EtOH, 
MeOH 
198-200 
(decomposes) 
Cefoperazone 645.7 0.286 
(slightly 
soluble) 
Weak acid MeOH 169-171 
Glycopeptides      Mainly Gram-
positive bacteria. 
Mycobacteria 
Vancomycin 1449.3 >100 
(highly 
soluble) 
Amphoteric DMSO 185-188 
Macrolides      Gram-positive and 
fastidious Gram-
negative bacteria 
Erythromycin 733.9 1.44 
(slightly 
soluble) 
Weak base High: MeOH, 
EtOH, 
Acetone, 
ACN, CHCl3, 
EtOAc, Ether, 
DMF, DMSO. 
Low: hexane, 
toluene 
191 
Nitromidazoles      Most anaerobes 
Metronidazole 171.2 10 (soluble) Lipophilic, 
low ionisation 
High: EtOH. 
Low: Ether, 
158-190 
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CHCl3 
Penicillins      Gram-positive and 
some Gram-
negative bacteria. 
Broader spectrum 
than most 
penicillins. 
Ampicillin 349.4 10.1 
(soluble) 
Acid High: MeOH, 
DMF. EtOH, 
Acetone, 
DMSO. Low: 
CHCl3 
199-202 
(decomposes) 
Polypeptides      Mainly Gram-
negative bacteria Colistin 
(polymyxin E) 
1155.4 564 (highly 
soluble) 
Base MeOH, DMF, 
DMSO. Low: 
Dioxane 
200-220 
Quinolones      Broad spectrum. 
More effective 
against Gram-
negative than Gram-
positive bacteria 
Ciprofloxacin 331.4 0.001 
(insoluble) 
Amphoteric High: MeOH, 
DMF, DMSO. 
Low: Dioxane 
255-257 
(decomposes) 
Ofloxacin 361.4 28.3 
(soluble) 
Amphoteric CHCl3. Low: 
EtOH, MeOH 
250-257 
(decomposes) 
Rifamycins      Gram-positive and 
fastidious Gram-
negative bacteria. 
Mycobacteria 
Rifampin/ 
Rifampicin 
823.0 1.4 (slightly 
soluble) 
Lipophilic, 
low ionisation 
DMSO, 
CHCl3, 
EtOAc, 
MeOH, THF. 
Low: Acetone  
183-188 
Tetracyclines      Broad spectrum, 
many Gram-positive 
and Gram-negative 
bacteria, 
mycoplasma. 
Doxycycline 444.5 0.63 
(slightly 
soluble) 
Amphoteric High: MeOH, 
Dioxane, 
DMF 
201 
Minocycline 457.5 52 (soluble) Amphoteric Low: EtOH N.A. 
Tetracycline 444.5 0.23 
(slightly 
soluble) 
Amphoteric High: 
Toluene, 
Ether, EtOAc, 
Acetone. 
Low: MeOH, 
EtOH, CHCl3, 
DMF, 
Dioxane 
165 
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Table C.2: Clarification of organic solvents listed in Table C.1 
Abbreviation Name Formula 
DMF Dimethylformamide C3H7NO 
MeOH Methanol CH3OH 
EtOH Ethanol C2H5OH 
Ether Diethyl ether C4H10O 
 Chloroform CHCl3 
 Acetone C3H6O 
DMSO Dimethyl sulfoxide C2H6OS 
 Pyridine C5H5 
AcN Acetonitrile C2H3N 
EtOAc Ethyl Acetate C4H8O2 
 Hexane C6H14 
 Toluene C7H8 
 Dioxane C4H8O2 
THF Tetrahydrofuran C4H8O 
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Appendix D: Vancomycin Liquid Chromatography-Mass 
Spectrometry 
 
The chromatographic method as applied at CAF is shown in the figure D.1 below. 
 
 
Figure D.1: Chromatographic gradient elution profile 
 
The equipment and setup information is reproduced directly from their report and is as follows: 
“Column: Waters UPLC HSS C18, 2.1x150mm, solvent A contained 1% formic acid and solvent 
B: acetonitrile.  Source: Electrospray positive, Capillary voltage 3 kV, Cone Voltage 15V, mass 
spectra were obtained by scanning from m/z 200-2000” 
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Figure D.2: Mass spectrum of vancomycin hydrochloride  
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Figure D.3: Resolved isotope mass spectrum within isotopic cluster at 2 charges 
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Appendix E: Simple Linear Regression for RP-HPLC 
Calibration Curves 
Consider the regressor and response variables x and Y, and let their relationship be linear with the 
response, Y, a random variable for each respective value of x.  The assumption is that the response 
is described by the straight line model, 
 
 𝑌 =  𝛽0 + 𝛽1𝑥 +  𝜖 (E.1) 
 
where 𝛽0, the intercept, and 𝛽1, the slope, are unknown regression coefficients.  The random 
error, 𝝐, has a mean of zero and an unknown variance, 𝜎2.   
 
The method of least squares is used for estimation of the regression coefficients. 
 
If there are n observations within the sample, it can be written as,  
 
 𝑦𝑖 =  𝛽0 +  𝛽1𝑥𝑖 + 𝜖𝑖,            i = 1, 2, … , n (E.2) 
 
with sum of the squares of any errors from the true linear relationship expressed as, 
 
 
𝐿 =  ∑ 𝜖𝑖
2
𝑛
𝑖=1
=  ∑(𝑦𝑖 − 𝛽0 −  𝛽1𝑥𝑖)
2
𝑛
𝑖=1
 (E.3) 
 
The intercept, 𝛽0 , and the slope, 𝛽1 , are estimated each with their respective least squares 
estimator, ?̂?0 and ?̂?1, which have to meet the criteria, 
 
 𝜕𝐿
𝜕𝛽0
| ?̂?0, ?̂?1 =  −2 ∑(𝑦𝑖 −  ?̂?0 −  ?̂?1𝑥𝑖)
𝑛
𝑖=1
= 0 
𝜕𝐿
𝜕𝛽1
| ?̂?0, ?̂?1 =  −2 ∑(𝑦𝑖 −  ?̂?0 −  ?̂?1𝑥𝑖)
𝑛
𝑖=1
𝑥𝑖 = 0 
(E.4) 
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when simplified leads to, 
 
 
𝑛?̂?0 +  ?̂?1  ∑ 𝑥𝑖
𝑛
𝑖=1
=  ∑ 𝑦𝑖
𝑛
𝑖=1
 
?̂?0  ∑ 𝑥𝑖 + ?̂?1  ∑ 𝑥𝑖
2
𝑛
𝑖=1
𝑛
𝑖=1
=  ∑ 𝑦𝑖𝑥𝑖
𝑛
𝑖=1
 
(E.5) 
 
which are also referred to as the least squares normal equations.  The least squares estimators  ?̂?0 
and ?̂?1 are obtained by solving the least squares normal equations. 
 
 ?̂?0 =  ?̅? − ?̂?1?̅? (E.6) 
 ?̂?1 =  
∑ 𝑦𝑖𝑥𝑖
𝑛
𝑖=1 − 
(∑ 𝑦𝑖
𝑛
𝑖=1 )(∑ 𝑥𝑖
𝑛
𝑖=1 )
𝑛  
∑ 𝑥𝑖
2 −  
(∑ 𝑥𝑖
𝑛
𝑖=1 )
2
𝑛
𝑛
𝑖=1
=  
𝑆𝑆𝑥𝑦
𝑆𝑆𝑥𝑥
=  
∑ (𝑦𝑖 − ?̅?)(𝑥𝑖 −  ?̅?)
𝑛
𝑖=1
∑ (𝑥𝑖 −  ?̅?)2
𝑛
𝑖=1
 (E.7) 
 
where ?̅? =  
1
𝑛
∑ 𝑦𝑖
𝑛
𝑖=1  and ?̅? =  
1
𝑛
∑ 𝑥𝑖
𝑛
𝑖=1  
 
𝑆𝑆𝑥𝑦 and 𝑆𝑆𝑥𝑥 are the respective sums of squares as denoted in the subscript of the notation. 
 
The regression line then becomes, 
 
 ?̂? =  ?̂?0 + ?̂?1𝑥 (E.8) 
 
Each pair of observations satisfies, 
 
𝑦𝑖 =  ?̂?0 +  ?̂?1𝑥𝑖 + 𝑒𝑖            i = 1,2, … , n 
 
where 𝑒𝑖 =  𝑦𝑖 −  ?̂?𝑖 is known as the residual.   
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The sum of squares of the residuals, also known as the error sum of squares, is 
 
 
𝑆𝑆𝐸 =  ∑ 𝑒𝑖
2
𝑛
𝑖=1
=  ∑(𝑦𝑖 −  ?̂?𝑖)
2
𝑛
𝑖=1
 (E.9) 
 
The regression sum of squares for Y is, 
 
 
𝑆𝑆𝑅 =  ∑ (?̂?𝑖 − ?̅?)
2
𝑛
𝑖=1
 (E.10) 
 
The total sum of squares with regard to the response variably Y is,  
 
 
𝑆𝑆𝑇 =  ∑ (𝑦𝑖 −  ?̅?)
2
𝑛
𝑖=1
 (E.11) 
 
which is also the sum of the regression and error sums of squares,  
 
 𝑆𝑆𝑇 =  𝑆𝑆𝐸 +  𝑆𝑆𝑅 (E.12) 
 
The sums of squares are used in determining the ratio R
2
, the coefficient of determination, 
 
 
𝑅2 =  
𝑆𝑆𝑅
𝑆𝑆𝑇
= 1 −  
𝑆𝑆𝐸
𝑆𝑆𝑇
 (E.13) 
 
It is typically utilised as a measure of adequacy of a regression model.  It is an indication of the 
regression model’s ability to account for variability in the observations, where 1 represents a 
100% fit.  Therefore, the closer the coefficient of determination is to one, the better the fit of the 
regression model. 
 
A series of screen shots from MSExcel follows which represents the application of the above 
process to determine the calibration curves for the RP-HPLC procedure. 
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 First standard series injection with 254 nm detection: 
 
 
Figure E.1: Response data for first standard series injection with 254 nm detection 
 
 
Figure E.2: MSExcel regression function output for linear estimation of calibration curve 
 
 
Figure E.3: Manual calculation results for regression parameters 
n = 7
Obs# oi x y xy y^2 x^2 xbar ybar
1 0 178681 0 31926899761.0000 0.00 66.7857 1385662.4286
2 5 244618 1223090 59837965924.0000 25.00
3 12.5 395502 4943775 156421832004.0000 156.25
4 25 652763 16319075 426099534169.0000 625.00
5 50 1119492 55974600 1253262338064.0000 2500.00
6 125 2497347 3.12E+08 6236742038409.0000 15625.00
7 250 4611234 1.15E+09 21263479002756.0000 62500.00
SUMMARY OUTPUT
Regression Statistics
Multiple R 0.999665984
R Square 0.999332079
Adjusted R Square 0.999198495
Standard Error 46213.16251
Observations 7
ANOVA
df SS MS F Significance F
Regression 1 1.59767E+13 1.59767E+13 7480.917271 3.91557E-09
Residual 5 10678281947 2135656389
Total 6 1.59873E+13
Coefficients Standard Error t Stat P-value Lower 95% Upper 95% Lower 95.0% Upper 95.0%
Intercept 194321.0839 22244.45365 8.735709446 0.000325606 137139.8954 251502.2724 137139.8954 251502.2724
X Variable 1 17838.26612 206.2410983 86.49229602 3.91557E-09 17308.1065 18368.42574 17308.1065 18368.42574
Sum x 467.5000
Sum y 9699637.0000
Sum x^2 81431.2500
Sum y^2 29427769611087.0000
Sum xy 1543437415
ß_hat_1 17838.2661236974
ß_hat_0 194321.08388
SSR 1.59767E+13
SSE 10678281947
SSR 1.59873E+13
R^2 0.999332079
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 First standard series injection with 280 nm detection: 
 
 
Figure E.4: Response data for first standard series injection with 280 nm detection 
 
 
Figure E.5: MSExcel regression function output for linear estimation of calibration curve 
 
 
Figure E.6: Manual calculation results for regression parameters 
n = 7
Obs# oi x y xy y^2 x^2 xbar ybar
1 0 36356 0 1321758736.0000 0.00 66.786 1264450.286
2 5 93726 468630 8784563076.0000 25.00
3 12.5 235294 2941175 55363266436.0000 156.25
4 25 484550 12113750 234788702500.0000 625.00
5 50 948790 47439500 900202464100.0000 2500.00
6 125 2360237 2.95E+08 5570718696169.0000 15625.00
7 250 4692199 1.17E+09 22016731455601.0000 62500.00
SUMMARY OUTPUT
Regression Statistics
Multiple R 0.999974327
R Square 0.999948654
Adjusted R Square 0.999938385
Standard Error 13442.37557
Observations 7
ANOVA
df SS MS F Significance F
Regression 1 1.75952E+13 1.76E+13 97373.61909 6.41435E-12
Residual 5 903487305.4 1.81E+08
Total 6 1.75961E+13
Coefficients Standard Error t Stat P-value Lower 95% Upper 95% Lower 95.0% Upper 95.0%
Intercept 14220.67866 6470.414145 2.1978 0.079313318 -2412.0504 30853.40773 -2412.0504 30853.40773
X Variable 1 18720.01551 59.99092361 312.0475 6.41435E-12 18565.80393 18874.22709 18565.80393 18874.22709
Sum x 467.50
Sum y 8851152.00
Sum x^2 81431.25
Sum y^2 2.8788E+13
Sum xy 1531042430.00
ß_hat_1 18720.02
ß_hat_0 14220.68
SSR 1.76E+13
SSE 9.0349E+08
SST 1.75961E+13
R^2 0.999949
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 Second standard series injection with 254 nm detection 
 
 
Figure E.7: Response data for second standard series injection with 254 nm detection 
 
 
Figure E.8: MSExcel regression function output for linear estimation of calibration curve 
 
 
Figure E.9: Manual calculation results for regression parameters 
n = 7
Obs# oi x y xy y^2 x^2 xbar ybar
1 0 178681 0 31926899761.0000 0.00 66.7857 1383306.4286
2 5 243882 1219410 59478429924.0000 25.00
3 12.5 391505 4893813 153276165025.0000 156.25
4 25 652588 16314700 425871097744.0000 625.00
5 50 1120264 56013200 1254991429696.0000 2500.00
6 125 2509887 3.14E+08 6299532752769.0000 15625.00
7 250 4586338 1.15E+09 21034496250244.0000 62500.00
SUMMARY OUTPUT
Regression Statistics
Multiple R 0.999513952
R Square 0.99902814
Adjusted R Square 0.998833769
Standard Error 55530.84387
Observations 7
ANOVA
df SS MS F Significance F
Regression 1 1.58494E+13 1.58494E+13 5139.776362 1.00009E-08
Residual 5 15418373104 3083674621
Total 6 1.58648E+13
Coefficients Standard Error t Stat P-value Lower 95% Upper 95% Lower 95.0% Upper 95.0%
Intercept 196719.7104 26729.46874 7.359656576 0.000727326 128009.4236 265429.9971 128009.4236 265429.9971
X Variable 1 17767.07386 247.8242476 71.69223362 1.00009E-08 17130.02135 18404.12636 17130.02135 18404.12636
Sum x 467.5000
Sum y 9683145.0000
Sum x^2 81431.2500
Sum y^2 29259573025163.0000
Sum xy 1538761498
ß_hat_1 17767.0738556745
ß_hat_0 196719.71035
SSR 1.58494E+13
SSE 15418373104
SST 1.58648E+13
R^2 0.99902814
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Figure E.10: Calibration curve for second standard series injection at 254 nm detection 
 
 Second standard series injection with 280 nm detection 
 
 
Figure E.11: Response data for second standard series injection with 280 nm detection 
 
 
Figure E.12: MSExcel regression function output for linear estimation of calibration curve 
n = 7
Obs# oi x y xy y^2 x^2 xbar ybar
1 0 36356 0 1321758736.0000 0.00 66.7857 1267355.1429
2 5 89054 445270 7930614916.0000 25.00
3 12.5 259945 3249313 67571403025.0000 156.25
4 25 487392 12184800 237550961664.0000 625.00
5 50 958742 47937100 919186222564.0000 2500.00
6 125 2379099 2.97E+08 5660112051801.0000 15625.00
7 250 4660898 1.17E+09 21723970166404.0000 62500.00
SUMMARY OUTPUT
Regression Statistics
Multiple R 0.999941319
R Square 0.999882641
Adjusted R Square 0.999859169
Standard Error 20194.22526
Observations 7
ANOVA
df SS MS F Significance F
Regression 1 1.73723E+13 1.73723E+13 42599.3 5.06627E-11
Residual 5 2039033670 407806733.9
Total 6 1.73743E+13
Coefficients Standard Error t Stat P-value Lower 95% Upper 95% Lower 95.0% Upper 95.0%
Intercept 25069.35222 9720.380156 2.579050595 0.049489 82.31956937 50056.38488 82.31956937 50056.38488
X Variable 1 18601.07066 90.123224 206.3959747 5.07E-11 18369.40154 18832.73978 18369.40154 18832.73978
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Figure E.13: Manual calculation results for regression parameters 
 
 
Figure E.14: Calibration curve for second standard series injection at 280 nm detection 
 
Sum x 467.5000
Sum y 8871486.0000
Sum x^2 81431.2500
Sum y^2 28617643179110.0000
Sum xy 1526428358
ß_hat_1 18601.0706618772
ß_hat_0 25069.35222
SSR 1.73723E+13
SSE 2039033670
SST 1.73743E+13
R^2 0.999882641
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